# ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 1 of 61

OVERVIEW AND ASSAY THEORY	5
SELECTSCREEN ASSAY CONDITIONS	9
SELECTSCREEN ASSAY CONTROLS	11
SELECTSCREEN DATA ANALYSIS	12
GPCR PROFILING CELL LINES AVAILABLE FOR SCREENING	13
PARENTAL CELL LINES AVAILABLE FOR SCREENING	17
CELL LINE-SPECIFIC ASSAY CONDITIONS	<b>18</b>
ADORA1 - bla U2OS - Antagonist Screen, Activated by NECA	
ADURAS - Dia U205 - Agonisi Screen ADURAS - Dia U205 - Antaonisi Screen, Activated by NECA	
ADRA1A - NFAT-bla CHO-K1 - Agonist Screen	
ADRA1A - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Phenylephrine	
ADRA1B - INFAT-bia CHO-K1 - Antagonist Screen, Activated by Phenylephrine	
ADRA2A - bla U2OS - Agonist Screen	
ADRA2A - bla U2OS - Antagonist Screen, Activated by UK 14304	
ADRA2A - Gqo5-NFAT-bia CH0-KT - Antagonist Screen, Activated by UK 14304	
ADRB1 - CRE-bla CHO-K1 - Agonist Screen	
ADRB1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by (-)Denopamine.	
ADR82 - ORE-bia CHO-K1 - Antagonist Screen, Activated by Isoproterenol.	20
ADRB3 - CRE-bla CHO-K1 - Agonist Screen	
ADRB3 - CRE-bla CHO-K1 - Antagonist Screen, Activated by BRL 37344.	
AGTR1 - bia U2OS - Agunist Screen. Activated by Angiotensin II.	20
AGTRL1 - bla U2OS - Agonist Screen	
AGTRL1 - bla U2OS - Antagonist Screen, Activated by Apellin-13.	
AVPR1A - NFAT-bia CHO-K1 - Antaoonist Screen. Activated by dAVP.	21
AVPR2 - CRE-bla CHO-K1 - Agonist Screen	
AVPR2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by dDAVP.	
B1 - NFAT-bia CHO-K1 - Applies Ceteen, Activated by Bradykinin.	22
B2 - NFAT-bla CHO-K1 - Agonist Screen	
B2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Bradykinin Acetate	
CSAR1 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by C5a	
CALCR - CRE-bla Freestyle 293F - Agonist Screen	
CALCR - CRE-bia Freestyle 2937 - Antagonist Screen, Activated by SC1	
CALCRL:RAMP1 - CRE-bil Freestyle 293 - Adaptins Goterin, Activated by CGRP	
CALCRL:RAMP3 - CRE-bla Freestyle 293F - Agonist Screen	
CALCRL:RAMP3 - CRE-bla Freestyle 293F - Antagonist Screen, Activated by Adrenomedullin	
CaSR - Gq0-FNAT-bla CHO-K1 - Antagonist Screen, Activated by Spermine.	
CCKAR - NFAT-bla HEK 293T - Agonist Screen	
CCKAR - NFAT-bla HEK 293T - Antagonist Screen, Activated by CCK-8.	
CKBR - NFAT-bia HEK 293T - Anglinist Screen. Activated by CCK-8.	24
CCR1 - bla U2OS - Agonist Screen	
CCR1 - bla U2OS - Antagonist Screen, Activated by Mip1-alpha	
CCR2 - bia U2OS - Andaonist Screen. Activated by MCP-1	
CCR3 - bla U2OS - Agonist Screen	
CCR3 - bla U2OS - Antagonist Screen, Activated by Eotaxin	
CR4 - bia U2OS - Andraionist Screen, Activated by MDC	
CCR5 - bla U2OS - Agonist Screen	
CCR5 - bla U2OS - Antagonist Screen, Activated by Mip1-alpha	
CR6 - bla U2OS - Antaonist Screen. Activated by Mio3-aloha.	
CCR7 - bla U2OS - Agonist Screen	
CCR7 - bla U2OS - Antagonist Screen, Activated by Mip3-beta	
UmpLr I - Dia U2US - Ayunisi Screen Activated hy Chemerin CMK I R 1, ha 11/DS - A hataonist Screen Activated hy Chemerin	
CNR1 - Galpha15-NFAT-bla CHO-K1 - Agonist Screen	
CNR1 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by CP-55940	
UNIZ - DIA UZUS - Agonist Screen. CNP2 - bia UZUS - Autonnist Screen Artivated by CP-55940	
CRHR1 - CRE-bla CHO-K1 - Agonist Screen	
CRHR1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by CRF	
CKHK2 - CKE-bia CHO-K1 - Agonist Screen	
UKHKZ - UKE-DIA UHU-K1 - ANTAGONIST SCREEN, ACTIVATED by UKF	

# ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 2 of 61

CXCR1 - bla U2OS - Antagonist Screen, Activated by IL-8	
CXCR2 - bla U2OS - Agonist Screen	
CXCR2 - bla U2OS - Antagonist Screen, Activated by IL-8	
CXCR3 - bia U2US - Agonist Screen	
CXCR3 - DIa U2OS - Antagonist Screen, Activated by I-IAC	
CKCR4 - bla U2OS - Antagonist Screen, Activated by SDF1-alpha	
CXCR6 - bla U2OS - Agonist Screen	
CXCR6 - bla U2OS - Antagonist Screen, Activated by CXCL16	
CXCR7 - bla U205 - Agonist Screen	
CAUK / DIA UZUS - Antagonisis Screen, Activated by SDF1-alpha	
cyst 2 - WAT-bia CHO-KI - Antaonist Screen. Activated by LTD4	
D1 - CRE-bla CHO-K1 - Agonist Screen	
D1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by Dihydrexidine	
D1 - CRE-bla CHO-K1 - Agonist Screen	
D2 - Gq05-NFAI-Dia CHO-A1 - Agonist Screen.	
EDG1 - bla U2OS - Antagonist Screen, Activated by S1P	
EDG2 - bla U2OS - Agonist Screen	
EDG2 - bla U2OS - Antagonist Screen, Activated by LPA (18:1).	
EUG3 - Galpha15-NFA1-bla HEK 2931 - Aggonist Screen. EDG3 - Galpha16 NEAT - Natagenist Screen Activited by S1P	
Loos - dapina contra contra contractor - Antagonis Screen, Activated by Str.	
EDG4 - bla U2OS - Antagonist Screen, Activated by LPA (18:1)	
EDG6 - bla U2OS - Agonist Screen	32
LUG6 - DIa UZOS - Antagonist Screen, Activated by S1P	
LUU / NRAI-DIA IEC 2331 - Agonist Screen	
EDG8 - bla U2OS - Agonist Screen	
EDG8 - bla U2OS - Antagonist Screen, Activated by S1P	
EDNRA - bla U2OS - Agonist Screen	
EDNRA - bia U2OS - Antagonist Screen, Activated by ET-1.	
EUNKA - NFAI-hild HEK 2931 - Agonist Screen	
EDING - IN AT-bia HEK 2931 - Agnagonas Octeen, Activated by ET-	
EDNRB - NFAT-bla HEK 293T - Antagonist Screen, Activated by ET-1	
F2RL1 - bla U2OS - Agonist Screen	
F2RL1 - bla U2OS - Antagonist Screen, Activated by SLIGRL-NH2	
rrkti - Galphats-NrA - Dia Chu-ki - Agonist Screen. EDI 1. Galphats-NrA - Dia Chu-ki - Antagonist Screen. Activated by WK/MWM pontide	
GALR1 - bla U2OS - Antagonist Screen, Activated by Galanin	
GALR2 - bla U2OS - Agonist Screen	35
GALR2 - bla U2OS - Antagonist Screen, Activated by Galanin (1-30)	
GCGR - CRE-bla CHO-K1 - Agonist Screen	
GISR - TREValu (2005) - Antaonist Green, Constitutively Activated	
GIPR - CRE-bla HEK 293T - Agonist Screen	
GIPR - CRE-bla HEK 293T - Antagonist Screen, Activated by Gastric Inhibitory Peptide	
GLP1R - CRE-bla CHO-K1 - Agonist Screen	
GLP1K - CKE-bla CHO-K1 - Antagonist Screen, Activated by GLP-1	
GLP2R - bia 02005 - Agoinst obteen GLP2R - bia 02005 - Antaonist Screen. Activated by GLP-2	
GnRHR - NFAT-bla CHO-K1 - Agonist Screen	
GnRHR - NEAT-bla CHO-K1 - Antagonist Screen Activated by I H-RH	
GPR1 - bla U2OS - Agonist Screen	
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin GPR1 - bl	
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin. GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin. GPR10 - NFAT-bla CHO-K1 - Antagonist Screen. Activated by PrRP20	
GPR1 - bla U2OS - Agonist Screen. GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin. GPR10 - NFAT-bla CHO-K1 - Agonist Screen GPR10 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by PrRP20. GPR109 - NFAT-bla U2OS - Agonist Screen.	
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin. GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin. GPR10 - NFAT-bla CHO-K1 - Agonist Screen GPR109 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by PrRP20 GPR109A - bla U2OS - Agonist Screen, Activated by Nicotinic Acid.	37 
GPR1 - bla U2OS - Agonist Screen, GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin GPR1 0- NFAT-bla CHO-K1 - Agonist Screen GPR10 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by PrRP20 GPR109A - bla U2OS - Angonist Screen, Activated by PrRP20 GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid	37 37 37 37 37 38 38 38
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin GPR10 - NFAT-bla CHO-K1 - Agonist Screen GPR109 - NFAT-bla LZOS - Antagonist Screen, Activated by PrR20 GPR109A - bla U2OS - Antagonist Screen GPR109A - bla U2OS - Antagonist Screen GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid GPR109A - bla U2OS - Antagonist Screen GPR109A - bla U2OS - Antagonist Screen	37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Agonist Screen,       Activated by Chemerin.         GPR1 - bla U2OS - Antagonist Screen,       Activated by Chemerin.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen,       Activated by PrRP20.         GPR109 - NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109 - NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109 - NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109 - NFAT-bla CHO-K1 - Antagonist Screen,       Activated by Nicotinic Acid.         GPR109 - NFAT-CRE-bla CHO-K1 - Antagonist Screen,       Activated by AR231453.         GPR1109 - TREx-CRE-bla CHO-K1 - Antagonist Screen,       Activated by AR231453.         GPR1205 - bla U2OS - Angonist Screen,       Activated by GW9508.	37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Agonist Screen,       Activated by Chemerin.         GPR1 - bla U2OS - Antagonist Screen,       Activated by Chemerin.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen,       Activated by PrRP20.         GPR109. NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109. NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109. NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109. NFAT-bla CHO-K1 - Antagonist Screen,       Activated by Nicotinic Acid.         GPR109. NFAT-bla CHO-K1 - Antagonist Screen,       Activated by Nicotinic Acid.         GPR109. TRX-CRE-bla CHO-K1 - Antagonist Screen,       Activated by AR231453.         GPR1109. TRX-CRE-bla CHO-K1 - Antagonist Screen,       Activated by AR231453.         GPR1208 - bla U2OS - Agonist Screen,       Activated by GW9508.         GPR1208 - bla U2OS - Antagonist Screen,       Activated by GW9508.         GPR38 - bla U2OS - Agonist Screen,       Mctivated by GW9508.	37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bla U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen.         GPR109 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR109 - NFAT-SCRE-bla CHO-K1 - Antagonist Screen.         GPR109 - NFAT-SCRE-bla CHO-K1 - Antagonist Screen.         GPR109 - Sta U2OS - Antagonist Screen.         GPR109 - Sta U2OS - Antagonist Screen.         GPR109 - Sta U2OS - Antagonist Screen.         GPR109 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR109 - Sta U2OS - Antagonist Screen.         GPR1205 - Sta U2OS - Antagonist Screen.         GPR1205 - Sta U2OS - Antagonist Screen.         GPR3 - Sta U2OS - Antagonist Screen.         GPR3 - Sta U2OS - Antagonist Screen.	37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR110 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR110 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR4 (CRTH2) - bia U2OS - Antagonist Screen.         GPR4 (CRTH2) - bia U2OS - Antagonist Screen.	37 37 37 37 37 37 37 37 37 37 37 37 37 3
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by PrRP20.         GPR109A - bia U2OS - Agonist Screen, Activated by PrRP20.         GPR109A - bia U2OS - Antagonist Screen, Activated by Nicotinic Acid.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR1205 - bia U2OS - Agonist Screen, Activated by AR231453.         GPR1205 - bia U2OS - Antagonist Screen, Activated by GW9508.         GPR33 - bia U2OS - Antagonist Screen, Activated by Zeprinast.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Zeprinast.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Indomethicin.	37 37 37 37 37 37 37 37 37 37 37 37 37 3
GPR1 - bla U2OS - Aggonist Screen, Activated by Chemerin.         GPR1 - bla U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Agnosit Screen.         GPR109A - bla U2OS - Agonist Screen.         GPR109A - bla U2OS - Agonist Screen.         GPR119 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR119 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR119 - NFX-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TFXx-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TFXx-CRE-bla CHO-K1 - Antagonist Screen.         GPR1205 - bla U2OS - Aggonist Screen.         GPR1205 - bla U2OS - Aggonist Screen.         GPR1205 - bla U2OS - Antagonist Screen.         GPR1205 - bla U2OS - Antagonist Screen.         GPR36 - bla U2OS - Aggonist Screen.         GPR36 - bla U2OS - Antagonist Screen.         GPR36 - bla U2OS - Antagonist Screen.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen.	37 37 37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR110 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR120 - Stal U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR4 (CRTH2) - bia U2OS - Antagonist Screen.         GPR44 (CRTH2) - bia U2OS -	37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Agonist Screen,       Activated by Chemerin.         GPR1 - bla U2OS - Antagonist Screen,       Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen,       Activated by PrRP20.         GPR109A - bla U2OS - Antagonist Screen,       Activated by PrRP20.         GPR109A - bla U2OS - Antagonist Screen,       Activated by PrRP20.         GPR109A - bla U2OS - Antagonist Screen,       Activated by PrRP20.         GPR109A - bla U2OS - Antagonist Screen,       Activated by Nicotinic Acid.         GPR119 - TREx-CRE-bla CHO-K1 - Antagonist Screen,       Activated by AR231453.         GPR120S - bla U2OS - Angonist Screen,       Activated by GW9508.         GPR120S - bla U2OS - Agonist Screen,       Activated by ZM9708.         GPR35 - bla U2OS - Antagonist Screen,       Activated by ZM9708.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen,       Activated by Indomethicin.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen,       Activated by Indomethicin.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen       Activated by Indomethicin.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen       Activated by Indomethicin.         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen       Activated by Metastin (45-54).         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen       Activated by Metastin (45-54).         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen       A	37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Angonist Screen, Activated by Chemerin.         GPR1 - NEAT-bla CHO-K1 - Agonist Screen, Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Angonist Screen.         GPR10 - NFAT-bla CHO-K1 - Angonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR110 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR111 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR1205 - bla U2OS - Antagonist Screen.         GPR35 - bla U2OS - Antagonist Screen.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen.         GPR45 - NFAT-bla CHO-K1 - Antag	37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR1205 - bia U2OS - Antagonist Screen.         GPR1205 - bia U2OS - Antagonist Screen.         GPR1205 - bia U2OS - Antagonist Screen.         GPR35 - bia U2OS - Antagonist Screen.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen.         GPR44 (CRT	37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR109A - bia U2OS - Antagonist Screen.         GPR109A - bia U2OS - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Agonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR1195 - Star U2OS - Antagonist Screen.         GPR1195 - Star U2OS - Antagonist Screen.         GPR1195 - Star U2OS - Antagonist Screen.         GPR1205 - bia U2OS - Antagonist Screen.         GPR1205 - bia U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen.         GPR45 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR46 - NFAT-bia CHO-K1 - Antagonist Screen. <td>37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38</td>	37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Angonist Screen, Activated by Chemerin.         GPR1 - Nata Value Chevit - Agonist Screen, Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR110 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR111 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR1205 - bla U2OS - Antagonist Screen.         GPR35 - bla U2OS - Antagonist Screen.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen.         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR45 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR8 - bla U2OS - Antagoni	37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Angonist Screen, Activated by Chemerin.         GPR1 - NBAT-bla CHO-K1 - Agonist Screen.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR110 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR111 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR112 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR113 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR1208 - bla U2OS - Antagonist Screen.         GPR1208 - bla U2OS - Antagonist Screen.         GPR1208 - bla U2OS - Antagonist Screen.         GPR13 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR4 (CRTH2) - bla U2OS - Antagonist Screen.	37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - bia U2OS - Antagonist Screen, Activated by PrRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen.         GPR109A - bia U2OS - Antagonist Screen.         GPR109A - bia U2OS - Antagonist Screen.         GPR119 - TREx-CRE-bia CHO-K1 - Antagonist Screen.         GPR109A - bia U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR3 - bia U2OS - Antagonist Screen.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen.	37 37 37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Angonist Screen, Activated by Chemerin.         GPR1 - Na Value Chever, Activated by PrRP20.         GPR10 - NFAT-bla CHO-K1 - Angonist Screen.         GPR109 - NEAT-bla CHO-K1 - Antagonist Screen.         GPR109 - NEAT-bla CHO-K1 - Antagonist Screen.         GPR109 - NEAT-bla CHO-K1 - Antagonist Screen.         GPR109 - NEAT-CRE-bla CHO-K1 - Antagonist Screen.         GPR109 - NEAT-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TREx-CRE-bla CHO-K1 - Antagonist Screen.         GPR1205 - bla U2OS - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen.         GPR4 (LCTH2) - bla U2OS - Antagonist	37 37 37 37 37 37 37 37 37 37 37 37 38 38 38 38 38 38 38 38 38 38 38 38 38
GPR1 - bla U2OS - Agonist Screen, Activated by Chemerin.         GPR1 - Natagonist Screen, Activated by PrR20.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen.         GPR10 - NFAT-bla CHO-K1 - Antagonist Screen.         GPR10 - NFAT-bla CHO-K1 - Agonist Screen.         GPR11 - TREX-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TREX-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TREX-CRE-bla CHO-K1 - Antagonist Screen.         GPR119 - TREX-CRE-bla CHO-K1 - Antagonist Screen.         GPR129 - Star U2OS - Antagonist Screen.         GPR129 - TREX-CRE-bla CHO-K1 - Agonist Screen.         GPR129 - Star U2OS - Antagonist Screen.         GPR129 - TREX-CRE-bla CHO-K1 - Aponist Screen.         GPR120S - bla U2OS - Antagonist Screen.         GPR120S - bla U2OS - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR3 - bla U2OS - Antagonist Screen.         GPR44 (CRTH2) - bla U2OS - Antagonist Screen.         GPR4 (SRTH2) - bla U2OS - Antagonist Screen.         GPR4 + NFAT-bla CHO-K1 - Agonist Screen.         GPR4 - NFAT-bla CHO-K1 - Agonist Screen. <td>37 37 37 37 37 37 37 37 37 37</td>	37 37 37 37 37 37 37 37 37 37
GPR1 - bia U2OS - Agonist Screen, Activated by Chemerin         GPR1 - bia U2OS - Antagonist Screen, Activated by PRP20.         GPR10 - NFAT-bia CHO-K1 - Agonist Screen, Activated by PRP20.         GPR103A - bia U2OS - Agonist Screen, Activated by Nicotinic Acid         GPR119 - TREX-CRE-bia CHO-K1 - Agonist Screen, Activated by AR231453.         GPR129 - TREX-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR129 - TREX-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR120S - bia U2OS - Agonist Screen, Activated by GW9508.         GPR35 - bia U2OS - Agonist Screen, Activated by GW9508.         GPR35 - bia U2OS - Agonist Screen, Activated by Zaprinast.         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Momethicin         GPR44 (CRTH2) - bia U2OS - Antagonist Screen, Activated by Metastin (45-54).         GPR4 + NFAT-bia CHO-K1 - Agonist Screen, Activated by Metastin (45-54).         GPR8 - bia U2OS - Antagonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Agonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Agonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP.         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP.	3333 3333 33333 33333 33333 33333 33333 3333
OPR1 - bia U20S - Appoints Green       Antagonist Screen, Activated by Chemerin         OPR1 - bia U20S - Appoints Screen, Activated by PrRP20         OFR10 - NFAT-bia CHO-K1 - Appoints Screen, Activated by PrRP20         OFR105A - bia U20S - Appoints Screen, Activated by Nicotinic Acid         OFR110 - NFAT-bia CHO-K1 - Appoints Screen, Activated by AR231453         OFR120S - bia U20S - Appoints Screen, Activated by AR231453         OFR120S - bia U20S - Appoints Screen, Activated by GW9508         OFR120S - bia U20S - Appoints Screen, Activated by GW9508         OFR120S - bia U20S - Appoints Screen, Activated by Zaprinast         OFR44 (CRTH2) - bia U20S - Appoints Screen         OFR45 + NFAT-bia CHO-K1 - Appoints Screen         OFR45 + NFAT-bia CHO-K1 - Appoints Screen         OFR4 + NFAT-bia CHO-K1 - Appoints Screen         OFR4 + NFAT-bia CHO-K1 - Appoints Screen         OFR4 - NFAT-bia CHO-K1 - Appoints Screen         OFR4 + NFAT-bia CHO-K1 - Appoints Screen         OFR4 - NFAT-bia CHO-K1 - Appoints Screen	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - bia U2OS - Aragonist Screen GPR1 - bia U2OS - Aragonist Screen, Activated by PrP20. GPR10 - NFAT-bia CHO-K1 - Aragonist Screen, Activated by PrP20. GPR108 - bia U2OS - Aragonist Screen, Activated by Nicotinic Acid GPR109 - Fib U2OS - Aragonist Screen, Activated by Nicotinic Acid GPR119 - TFEX-CRE-bia CHO-K1 - Aragonist Screen, Activated by AR231453 GPR120 - Fib U2OS - Aragonist Screen, Activated by GPR908 GPR120 - Fib U2OS - Aragonist Screen, Activated by GP808 GPR120 - Fib U2OS - Aragonist Screen, Activated by GP808 GPR210 - Fib U2OS - Aragonist Screen, Activated by GP808 GPR25 - bia U2OS - Aragonist Screen, Activated by Indomethicin GPR44 (CRTH2) - bia U2OS - Aragonist Screen, Activated by Metastin (45-54) GPR44 (CRTH2) - bia U2OS - Aratognist Screen, Activated by Metastin (45-54) GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GP808 GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GP808 GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by Metastin (45-54) GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by Metastin (45-54) GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by Metastin (45-54) GPR54 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by GRP H1 - NFAT-bia CHO-K1 - Anagonist Screen, Activated by Histamine H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by Histamine H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by Histamine H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by Histamine H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by Histamine H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by CRE H1 - NFAT-bia CHO-K1 - Agonist Screen, Activated by Metastinie H2 - CRE-bia HEX 231 - Anagonist Screen, Activated by Metastinie H2 - CRE	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - bia U203 - Aragonist Screen       Activated by Chemerin         GPR1 - Ivia U203 - Antagonist Screen       Activated by PrP20         GPR10 - IVFAT-bia CHO-K1 - Antagonist Screen       Activated by PrP20         GPR104 - Ivia U203 - Antagonist Screen       Activated by PrP20         GPR1054 - bia U203 - Antagonist Screen       Activated by Neotinic Acti         GPR119 - TREX-CRE-bia CHO-K1 - Antagonist Screen       Activated by AR231453         GPR119 - TREX-CRE-bia CHO-K1 - Antagonist Screen       Activated by AR231453         GPR1205 - bia U203 - Agonist Screen       Activated by CM9508         GPR35 - bia U203 - Antagonist Screen       Activated by CM9508         GPR35 - bia U203 - Antagonist Screen       Activated by CM9508         GPR44 (CRTH2) - bia U203 - Adonist Screen       Activated by Indomethicin         GPR44 (CRTH2) - bia U203 - Adonist Screen       GPR44 (CRTH2) - bia U203 - Adonist Screen         GPR44 (CRTH2) - bia U203 - Adonist Screen       GPR44 (CRTH2) - bia U203 - Adonist Screen         GPR4 - NFAT-bia CHO-K1 - Agonist Screen       GPR44 (CRTH2) - bia U203 - Adonist Screen         GPR4 - NFAT-bia CHO-K1 - Antagonist Screen       GPR44 (CRTH2) - bia U203 - Adonist Screen         GPR4 - NFAT-bia CHO-K1 - Antagonist Screen       GPR44 (CRTH2) - bia U203 - Antagonist Screen         GPR4 - NFAT-bia CHO-K1 - Antagonist Screen       GPR44 (CRTH2) - bia U203 - Antagonist Screen	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - bia U20S - Antagonist Screen       Activated by Chemerin         GPR1 - bia U20S - Antagonist Screen, Activated by PrR20         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by PrR20         GPR110 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Nicotinic Acid         GPR110 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Nicotinic Acid         GPR119 - TEX-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR120S - bia U20S - Antagonist Screen, Activated by GW9508.         GPR320S - bia U20S - Antagonist Screen, Activated by GW9508.         GPR35 - bia U20S - Antagonist Screen, Activated by Taprinast.         GPR44 (CRTH2) - bia U20S - Antagonist Screen, Activated by Indomethicin         GPR44 (CRTH2) - bia U20S - Antagonist Screen, Activated by Indomethicin         GPR45 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Metastin (45-54).         GPR8 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Metastin (45-54).         GPR8 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by REP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by REP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by GRP         H1 - NFAT-bia CHO-K1 - Antag	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - Iba I2OS - Antagonist Screen, Activated by Chemerin         GPR1 - Iba I2OS - Antagonist Screen, Activated by PRP20         GPR10 - NFAT-Iba CHO-K1 - Antagonist Screen, Activated by PRP20         GPR10 - NFAT-Iba CHO-K1 - Antagonist Screen, Activated by Nicotinic Acid.         GPR119 - TREX-CRE-Iba CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR1295 - Iba I2OS - Antagonist Screen, Activated by Nicotinic Acid.         GPR1295 - Iba I2OS - Antagonist Screen, Activated by Vies508.         GPR32 - Iba I2OS - Antagonist Screen, Activated by GPV         GPR35 - Iba I2OS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRTH2) - Iba I2OS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRTH2) - Iba I2OS - Antagonist Screen, Activated by Indomethicin.         GPR45 - Iba I2OS - Antagonist Screen, Activated by Neuropeptide B-29.         GPR4 - NFAT-Iba CHO-K1 - Angonist Screen, Activated by Metastin (45-54).         GPR8 - Iba IZOS - Antagonist Screen, Activated by GRP         GPR8 - Iba IZOS - Antagonist Screen, Activated by GRP         GPR8 - Iba IZOS - Antagonist Screen, Activated by GRP         HT - Iba CHO-K1 - Angonist Screen, Activated by Histamine         H2 - CRE-Iba IHEK 2337 - Agonist Screen, Activated by Histamine         H2 - CRE-Iba IHEK 2337 - Antagonist Screen, Activated by Istamine         H3 - Iba IZOS - Antagonist Screen, Activated by Istamine         H4 - Iba IZOS - Antagonist Screen, Activated by Istamine	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - Iba U2OS - Antagonist Screen, Activated by Chemerin         GPR1 - Iba U2OS - Antagonist Screen, Activated by PRP20         GPR10 - NFAT-Iba CHO-K1 - Antagonist Screen, Activated by PRP20         GPR10 - NFAT-Iba CHO-K1 - Antagonist Screen, Activated by Nicotinic Acid         GPR19 - NFAT-Iba CHO-K1 - Antagonist Screen, Activated by Nicotinic Acid         GPR19 - NFAT-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR192 - Dia U2OS - Antagonist Screen, Activated by GW9508.         GPR20 - Sola U2OS - Antagonist Screen, Activated by GW9508.         GPR35 - Dia U2OS - Antagonist Screen, Activated by GW9508.         GPR35 - Dia U2OS - Antagonist Screen, Activated by GW9508.         GPR44 (CRTH2) - Ibia U2OS - Antagonist Screen, Activated by Indomethicin         GPR44 (CRTH2) - Ibia U2OS - Antagonist Screen, Activated by Indomethicin         GPR44 (CRTH2) - Ibia U2OS - Antagonist Screen, Activated by Metastin (45-54).         GPR4 - ISTA U2OS - Antagonist Screen, Activated by Metastin (45-54).         GPR4 - INFAT-Ibia CHO-K1 - Anagonist Screen, Activated by Metastin (45-54).         GPR4 - INFAT-Ibia CHO-K1 - Anagonist Screen, Activated by GPR         H1 - INFAT-Ibia CHO-K1 - Anagonist Screen, Activated by GPR         H1 - NFAT-Ibia CHO-K1 - Anagonist Screen, Activated by GPR         H1 - NFAT-Ibia CHO-K1 - Anagonist Screen, Activated by Histamine         H2 - CRE-Ibia HEK 233T - Antagonist Screen, Activated by Histamine         H2 - CRE-Ibia HEK	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
GPR1 - bia (J2OS - Antagonist Screen         GPR1 - bia (J2OS - Antagonist Screen, Activated by PrP20.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by PrP20.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by PrP20.         GPR10 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Netzitated D.         GPR19 - NEAT-CRE-bia CHO-K1 - Antagonist Screen, Activated by AR231453.         GPR193 - Nia UZOS - Antagonist Screen, Activated by QW9508.         GPR32 - bia UZOS - Antagonist Screen, Activated by ZPATIANS.         GPR35 - bia UZOS - Antagonist Screen, Activated by Japrinast.         GPR44 (CRT142) - bia UZOS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRT142) - bia UZOS - Antagonist Screen, Activated by Indomethicin.         GPR44 (CRT142) - bia UZOS - Antagonist Screen, Activated by Metastin (45-54).         GPR45 - INZ UZOS - Antagonist Screen, Activated by Metastin (45-54).         GPR48 - NFAT-bia CHO-K1 - Agonist Screen, Activated by Metastin (45-54).         GPR48 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by Metastin (45-54).         GPR48 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by REP         H1 - NFAT-bia CHO-K1 - Antagonist Screen, Activated by REP         H2 - CRE-bia HEK 2331 - Antagonist Screen, Activated by Metastine         H2 - CRE-bia HEK 2331 - Antagonist Screen, Activated by Metastine         H2 - CRE-bia HEK 2331 - Antagonist Screen, Activated by Metastine         H2 - CRE-bia HEK 233	5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
OPR1 - Ibl U205 - Angonist Screen       Common	$\begin{array}{c} 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 $

# ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 3 of 61

HTR7_CRE-bla CHO_K1_Agoniet Screen	43
HTTP: CRE-bla CHO-K1 - Antanoniet Screen Activated by 5-HT	43
LTE4R - Galpha15-NFAT-bla CHO-K1 - Agonist Screen	43
LTB4R - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen. Activated by Leukotriene B4	44
M1 - NFAT-bla CHO-K1 - Agonist Screen	44
M1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol	44
M2 - bla U2OS - Agonist Screen	44
M2 - bla U2OS - Antagonist Screen, Activated by Carbachol	44
M3 - NFAT-bla CHO-K1 - Agonist Screen	44
M3 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol	45
M4 - bla U2OS - Agonist Screen	45
M4 - bla U2OS - Antagonist Screen, Activated by Carbachol	45
M4 - Gqo5-NFAT-bla CHO-K1 - Agonist Screen	45
M4 - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol	45
M5 - NFAT-bla CHO-K1 - Agonist Screen	45
M5 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol	45
MC1R - CRE-bla CHO-K1 - Agonist Screen	46
MC1R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH	46
MC2R - CRE-bla CHO-K1 - Agonist Screen	46
MC2R - CRE-bla CHO-K1 - Antagonist Screen, Activated by ACTH (1-24).	46
MC3R - CRE-bla CHO-K1 - Agonist Screen	46
MC3R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH	46
MC4R - CRE-bla CHO-K1 - Agonist Screen	47
MC4R - CRE-bla CHO-K1 - Antagonist Screen, Activated by alpha-MSH	47
MC5R - CRE-bla CHO-K1 - Agonist Screen	47
MC5R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH	47
MCHR1 (GPR24) - Gql5-NFA - bla CHO-K1 - Agonist Screen	47
MCHR1 (GPR24) - Gql5-NFA I-bla CHO-K1 - Antagonist Screen, Activated by MCH	47
Mutitz - Dia U2US - Agonist Screen	47
MCHRZ - bla U2OS - Antagonist Screen, Activated by MCH (6-17)	48
MUHIZ - NrAI-Dia UHU-R1 - Agonist Screen	48
MCHRZ - NFAI-Dia CHU-F1 - Antragonist Screen, Activated by MCH (6-17)	48
MINKTA - Dia UZUS - Agonist Screen	48
MINKTA - DIA U203 - Antiagonisti SCReen, Activated by Melatonin.	48
MINKTB - Dia V2US - Agonist sciel Screen	48
MINKTD - DIA U205 - ANTAGONIST SCREEN, ACTIVATED DY MEIATONIN.	48
NMUR1 - NFAI-bla CHO-R1 - Agonist Screen	49
NMURT - NFAI-bild CHU-R1 - Antagonist Screen, Activated by NMU-25.	49
NPSR1-A - NFAI-Dala CHU-Ki - Agonist Screen	49
NPSRT - A - NFAT - bia CHU-KT - Antragonist Screen, Activated by Neuropeptide S	49
NPSRT-B - NFAT-bla CHU-K1 - Agonist Screen	49
NPSKT-b - NFA1-bia CHO-h1 - Antagonist Screen, Activated by Neuropeptide S	49
NPTR - Dia UZOS - Agonist Screen	50
NPTR - Dia UZOS - Antagonist Screen, Activated by Neuropeptide T	50
NPTZR - Dia UZOS - Agonist Screen NPTZR - Dia UZOS - Agonist Screen NPTZR - Dia UZOS - Adonatis Screen	50
NPT2R - bia 0205 - Antagonist Screen, Activated by Neuropeptide 1	50
NISRI - NFAI-bia CHO-Ki - Agonist Screen	50
NISKI - NFAI-bia Chu-Ai - Antagonis Screen, Activated by Neurotensin	50
UPRD1 - bia U205 - Agonisi Screen	51
UPR/1 - Dia U205 - Antagonist Screen, Activated by SNC60	51
UPRAT - Dia UZUS - Agonisi Screen	51
UFINT - Did UZUS - Anlagunist Scient, Activated by USU4400	JI 61
UFINI - GUIS-INFAI-Jula CHO-NI - Aguinist Scienti ODDV/ - Case NEAT blo CHO VA Antragent Activited by UE0499	JI 61
OPRATI- GQO-NPAT-Dia CHO-NT - Antagonist Screen, Activated by US0466	51
UrnLi - Ula U200 - Aguitsi duleeli	52
OFRE1 - Did OZOS - Antagonist Scient, Activated by Nociceptin.	52
UrnLi - Odja-HrA i ola Freeslyle 2357 - Aguilist Suberli ODDI 1. Odli - Net Net Suberli 2025 - Astronaut Senson, Activited by Nacionatia	52
OFNET - Sqliphra Fuld Fleeslyle 2307 - Alitagoliisi Scleen, Activated by Nocceptin.	52
Urnmi - Did UCUS - Agvinsi Scheel. ODBMA bis 1005 - Astronomic Screen, Astrodek by DAMCO	52
	52
OATTE Gaos NEAT bis CHOKT - Agoinst Cotesti and by Oxytecin	52
DATIS - SQUSHITAT-DIA UNDATI - ANIAGUNISI SCIERII, ACIIVAREI DY OXYUUN	33
FAN LET IN A FOR OVERVEL ADVIS OUR DI	35 57
2PRY2. NFAT-hia CHO_K1_Anonist Screen	55
DRY2 - NFAT-bla CHO-K1 - Antaonois Screen Activated by ATP	55
DRY6, NFAT-hia CHO.K1 - Anonist Screen	55
P2RY6_NEAT-bla CHO_K1_Antanonist Screen_Activated by UDP	5/
PAC1 - CRE-bia CHO-K1 - Agonist Screen	
PAC1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by PACAP	54
PTAFR - bla U2OS - Aconist Screen	
PTAFR - bla U2OS - Aňtagonist Screen, Activated by PAF	
PTGDR - CRE-bla CHO-K1 - Agonist Screen	
PTGDR - CRE-bla CHO-K1 - Antagonist Screen, Activated by PGD2.	54
PTGER1 - NFAT-bla CHO-K1 - Agonist Screen	55
PTGER1 - NFAT-bla CHO-K1 - Antagonist Screen. Activated by PGE2	55
PTGER2 - CRE-bla CHO-K1 - Agonist Screen	55
PTGER2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by PGE2	55
PTGIR - CRE-bla CHO-K1 - Agonist Screen	55
PTGIR - CRE-bla CHO-K1 - Antagonist Screen, Activated by lloprost.	55
RLN3R1 - bla U2OS - Agonist Screen	56
RLN3R1 - bla U2OS - Antagonist Screen, Activated by Relaxin-3	56
SCTR - CRE-bla CHO-K1 - Agonist Screen	56
SCTR - CRE-bla CHO-K1 - Antagonist Screen, Activated by Secretin	56
SSTR1 - bla U2OS - Agonist Screen	56
SSTR1 - bla U2OS - Antagonist Screen, Activated by SST14	56
SSTR2 - bla U2OS - Agonist Screen	56
SSTR2 - bla U2OS - Antagonist Screen, Activated by SST14	57
SSTR5 - bla U2OS - Agonist Screen	57
SSTR5 - bla U2OS - Antagonist Screen, Activated by SST14	57
TACR1 - bla U2OS - Agonist Screen	57
TACR1 - bla U2OS - Antagonist Screen, Activated by Substance P	57
TACR2 - NFAT-bla CHO-K1 - Agonist Screen	57
TACR2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by (NIe10)-Neurokinin A (4-10)	58
TACR3 - bla U2OS - Agonist Screen	58
TACR3 - bla 1/2005 - Antagonist Screen, Activated by SSP Frag 6-11	
Thore - bid 0200 - Anagoniat Ocicen, Adatuated by Con Thag 0-11	58
TXA2R - bla U2OS - Agonist Screen	58 58

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 4 of 61

60

.. 60 .. 60 .. 60 .. 60 .. 61 .. 61 .. 61

VPAC1 - CRE-bla CHO-K1 - Agonist Screen	
VPAC1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by VIP	
VPAC2 - CRE-bla CHO-K1 - Agonist Screen	
VPAC2 - CRE-bla CHO-K1 - Antagonist Screen Activated by VIP	
the second second the state state of the second sec	

# PARENTAL CELL LINE-SPECIFIC ASSAY CONDITIONS

CRE-bla CHO-K1 - Agonist Screen CRE-bla Freestyle 293F - Agonist Screen Galpha15-NFAT-bla CHO-K1 - Agonist Screen Galpha15-NFAT-bla HEK 293T - Agonist Screen Gq5-NFAT-bla CHO-K1 - Agonist Screen Gq5-NFAT-bla CHO-K1 - Agonist Screen NFAT-bla CHO-K1 - Agonist Screen NFAT-bla HEK 293T - Agonist Screen NFAT-bla HEK 293T - Agonist Screen

**Thermo Fisher** 

SCIENTIFIC

**ThermoFisher** 

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 5 of 61

# **Overview and Assay Theory**

The SelectScreen Cell-based GPCR Profiling (SSCG) Service utilizes Life Technologies' growing library of functional and validated GeneBLAzer<sup>™</sup> and Tango<sup>™</sup> GPCR cell lines. Both of these GPCR signaling technologies, discussed in detail below, activate a stably integrated beta-lactamase (*bla*) reporter gene. When present, the *bla* enzyme cleaves the LiveBLAzer<sup>™</sup>-FRET B/G Loading Substrate to provide a selective and quantitative FRET-based readout of GPCR activity. The rapidly growing panel of targets available in the Service is available in two different formats, division arrested or cryo-preserved. While not a format included in our standard service options, dividing cells are sometimes utilized in the profiling service. Targets requiring the use of dividing cells within the service may be identified within the Cell Line-Specific Assay Conditions. The Service provides a reliable, rapid, and sensitive method of analyzing the status of a wide range of disease-relevant GPCRs upon exposure to drug candidates or other stimuli.

All GeneBLAzer and Tango GPCR cell lines used in the SelectScreen Cell-based GPCR Profiling (SSCG) Service provide superior response profiles as a result of optimization of assay conditions and selection of high-responding cell populations. Since the cell lines in the portfolio have been developed and extensively validated by Life Technologies, we ensure the consistency, reliability and performance of each cell line. Each of the GeneBLAzer and Tango GPCR cell lines:

Are division arrested or cryo-preserved to avoid variability associated with cell division

Provide ready-to-screen, ratiometric assays for disease relevant targets

Are functionally validated to ensure high-quality results each and every time

In order to evaluate non-specific effects when using GeneBLAzer GPCR technology, parental cell lines are included in the panel to allow counter-screening of the identified "hits" from the primary screen.

The GeneBLAzer and Tango cell lines in the Service are tested and documented to show a high level of performance. These assays have been designed and validated to meet the following specifications:

Z'-factor of 0.5 or greater for Agonist assays and Z'-factor of 0.4 or greater for Antagonist assays.

Appropriate EC<sub>50</sub>/IC<sub>50</sub> responses to known Agonists and Antagonists

Any assay results not meeting these specifications are automatically repeated until the results pass our QC criteria.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# How GeneBLAzer and Tango Technology works

Thermo Fisher

SCIENTIFIC

GeneBLAzer and Tango Technology use a mammalian-optimized Beta-lactamase reporter gene (*bla*) combined with a FRET-enabled substrate to provide reliable and sensitive detection in intact cells.

Cells are loaded with an engineered fluorescent substrate containing two fluorophores, coumarin and fluorescein. In the absence of *bla* expression, the substrate molecule remains intact. In this state, excitation of the coumarin results in fluorescence resonance energy transfer to the fluorescein moiety and emission of green light. However, when *bla* is expressed, the substrate is cleaved, separating the fluorophores, and disrupting energy transfer. Excitation of the coumarin in the presence of Beta-lactamase (*bla*) activity results in a blue fluorescence signal. The resulting coumarin:fluorescein ratio provides a normalized reporter response which can minimize experimental noise that can mask the underlying biological response of interest.



Figure 1. Fluorescent detection of cells using the GeneBLAzer and Tango<sup>™</sup> technology. After substrate loading, in the absence of Betalactamase, cells appear green. In the presence of Beta-lactamase, the substrate is cleaved and cells therefore appear blue.

**ThermoFisher** 

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# Detecting GPCR signaling using the GeneBLAzer Technology

GPCR signaling as detected by the GeneBLAzer Technology is mediated by trimeric G-proteins containing alpha, beta, and gamma subunits and can be categorized into signaling classes based upon the alpha-subunit composition.  $G_s$ ,  $G_q$ ,  $G_{i/o}$  proteins mediate intracellular signaling through activation of signaling pathways leading to distinct physiological endpoints. Activation of  $G_s$  and  $G_{i/o}$  coupled receptors leads to stimulation or inhibition of adenylate cyclase, respectively, while activation of  $G_q$  coupled receptors results in stimulation of phospholipase C. However, co-transfection with the promiscuous or chimeric  $G_{a15}$ ,  $G_{qi5}$ , or  $G_{qo5}$  G- proteins redirects this signaling through PLC. GPCR signaling through these distinct pathways thus can be monitored by modulation of specific transcriptional response elements placed upstream of the *bla*.



**Figure 2. GPCR activity using GeneBLAzer validated assays.** Schematic overview of the activation of GPCRs through distinct pathways and analysis of the response through the Beta-lactamase reporter gene system.

# **Thermo Fisher Screening Protocol and Assay Conditions** SCIENTIFIC Revised 07-07-2023

# **Detecting GPCR signaling using the Tango Technology**

GPCR signaling as detected by the Tango Technology is based upon the interaction of intracellular Betaarrestin proteins and the target receptor. Upon ligand binding to the target receptor, the protease tagged arrestin is stimulated and recruited to the protease site on the C-terminus of the GPCR, which triggers release of the tethered transcription factor. The free transcription factor then enters the nucleus and stimulates the *bla* activity.



Figure 3. GPCR activity using Tango<sup>™</sup>validated assays. Schematic overview of the activation of GPCRs through Beta-arrestin signaling pathway and analysis of the response through the Beta-lactamase reporter gene system.

**ThermoFisher** 

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 9 of 61

# SelectScreen ASSAY CONDITIONS

# **Test Compounds**

Test compounds are received at 1000X (or greater) of the desired starting concentration in 100% DMSO. If compounds are supplied at greater than 1000X concentration, an initial dilution is made in 100% DMSO to bring the compounds to 1000X concentration. The 1000X test compounds are serially diluted (10 point  $\frac{1}{2}$ -log increments) in 100% DMSO.

# Substrate Loading Solution

The Substrate Loading Solution consists of three reagents: Solution A (1 mM LiveBLAzer™-FRET B/G Substrate); Solution B, and Solution C.

# Agonist Assay Protocol

Plate type utilized and the addition of cells (Step 1) or compound (Step 2) first to the plate is dictated by each cell line and described in the Cell Line-Specific Assay Conditions.

Barcoded Corning 384 well Flat Clear Bottom Black Polystyrene TC-Treated Microplates (Corning Cat. #3712)

Barcoded Corning 384 well Flat Clear Bottom Black Polystyrene Poly-D-Lysine Coated Microplates (Corning Cat. #3664)

1. 32  $\mu$ L of cells diluted in Assay Media to appropriate cell density are added to the assay plate. If needed, cells are incubated at 37°C/5% CO<sub>2</sub> for 6 or 16-24 hours (depending upon cell line specifics) before compound is added.

2. 40 nL of 1000X compound or known activator titration plus 4  $\mu$ L of assay media is added to the cells in the assay plate.

3. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L.

4. The assay plate is incubated for 5 or 16 hours (depending upon cell line specifics) at  $37^{\circ}C/5\%$  CO<sub>2</sub> in a humidified incubator.

5. 8 µL of the Substrate Loading Solution is added to the assay plate.

6. The assay plate is incubated for 2 hours at room temperature, in the dark.

7. The assay plate is read on a fluorescence plate reader (Tecan Safire<sup>2</sup>) and the data is analyzed.

# Antagonist Assay Protocol

An Agonist assay screen is run to obtain the EC<sub>80</sub> concentration of the known activator to add in step 3.

1. 32  $\mu$ L of cells diluted in Assay Media to appropriate cell density are added to the assay plate. If needed, cells are incubated at 37°C/5% CO<sub>2</sub> for 6 or 16-24 hours (depending upon cell line specifics) before compound is added.

2. 40 nL of 1000X compound or known antagonist titration plus 4  $\mu$ L of Assay Media is added to the cells in the assay plate and incubated for 30 minutes at 37°C/5% CO<sub>2</sub> in a humidified incubator.

3. 4  $\mu$ L of the 10X EC<sub>80</sub> concentration of agonist, as determined in an Agonist assay, is added to all wells containing test compound and known inhibitor to bring the final assay volume to 40  $\mu$ L.

4. 4  $\mu$ L of Assay Media is added to remaining control wells to bring the volume up to 40  $\mu$ L.

5. The assay plate is incubated for 5 or 16 hours (depending upon cell line specifics) at  $37^{\circ}C/5\%$  CO<sub>2</sub> in a humidified incubator.

6. 8 μL of the Substrate Loading Solution is added to the assay plate.

ThermoFisher SCIENTIFIC	Screening Protocol and Assay (	Conditions Revised 07-07-2023
		Page 10 of 61

- 7. The assay plate is incubated for 2 hours at room temperature, in the dark.
- 8. The assay plate is read on a fluorescence plate reader (Tecan Safire<sup>2</sup>) and the data is analyzed.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# SelectScreen Assay Controls

Thermo Físher

SCIENTIFIC

The following controls are run on each plate for each individual cell-line:

# Full Agonist control

The full agonist control contains 0.1% DMSO, cells and a maximum concentration of the known agonist (stim). In agonist mode, the full agonist control is used to determine the upper end of the assay or 100% activation. In antagonist mode, the full agonist control is used to determine the actual  $EC_{80}$  used in the assay with the  $EC_{80}$  concentration chosen from previous agonist experiments.

# No Agonist control

The no agonist control contains 0.1% DMSO, cells and assay media in place of the agonist (stim). In agonist mode, it is used to determine the lower end of the assay or 0% activation. In antagonist mode, it is used to determine maximal inhibition or 100% inhibition.

# **Cell-free Control**

The cell-free control contains 0.1% DMSO and assay media. It is used to determine the background fluorescence for both coumarin and fluorescein wavelengths. This value is used for background subtraction.

# EC<sub>80</sub> Control (Antagonist mode only)

The  $EC_{80}$  control is a concentration of the known agonist in assay media that has been determined through an agonist experiment. In antagonist mode, the  $EC_{80}$  control is used to determine the actual baseline of activation or 0% inhibition.

# Known Agonist (Agonist mode) or Antagonist (Antagonist mode) Titration

A known agonist or antagonist titration is run on every plate for each cell-line to ensure the cell line is either activated or inhibited within an expected  $EC_{50}/IC_{50}$  range as previously determined.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# SelectScreen Data Analysis

**Thermo Fisher** 

SCIENTIFIC

The following equations are used for each set of data points:

	Equation					
Background-Subtracted Fluorescence (Fl = Fluorescence Intensity)	Fl <sub>Sample</sub> – Fl <sub>Cell-Free</sub> Ctrl					
<b>Emission Ratio</b> (using values corrected for background fluorescence)	Coumarin Emission (460 nm) Fluorescein Emission (530 nm)					
Response Ratio (Act. = Activation)	Emission Ratio Compound Emission Ratio No Agonist Ctrl					
% Activation – Agonist Assays	Response Ratio Compound – Response Ratio No Agonist Ctrl         Response Ratio Full Agonist Ctrl – Response Ratio No Agonist Ctrl					
% Inhibition – Antagonist Assays	{             1 -					
Z' - Agonist Assays (using Emission Ratio values)	1 - <u> 3*Std Dev Full Agonist Ctrl</u> + 3*Std Dev No Agonist Ctrl <u> Mean Full Agonist Ctrl</u> - Mean No Agonist Ctrl					
Z' - Antagonist Assays (using Emission Ratio values)	1 - <u> 3*Std Dev EC80 Ctrl</u> + 3*Std Dev No Agonist Ctrl <u> Mean EC80 Ctrl</u> - Mean No Agonist Ctrl					

# Graphing Software

SelectScreen Cell-Based GPCR Profiling Service uses XL*fit* from IDBS. The dose response curve is curve fit to model number 205 (sigmoidal dose-response model). Custom logic was built in-house for the data analysis tool to address the different compound characteristics that can be observed with functional assays. Using this logic the relative  $EC_{50}/IC_{50}$  value for each given compound is provided.

**ThermoFisher** 

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 13 of 61

# GPCR Profiling Cell Lines Available for Screening

Assay	Cell Line	Tech- nology	Agonist	EC50 (nM)	Antagonist	IC50 (nM)	Ag. Mode	Antag. Mode
ADORA1	bla U2OS	Tango	NECA	16.4	DPCPX	5.61	Yes	Yes
ADORA3	bla U2OS	Tango	NECA	66.5	MRS1220	0.459	Yes	Yes
ADRA1A	NFAT-bla CHO-K1	BLA	Phenylephrine	43.4	Prazosin	1.58	Yes	Yes
ADRA1B	NFAT-bla CHO-K1	BLA	Phenylephrine	71.05	Yohimbine	1081	Yes	Yes
ADRA2A	bla U2OS	Tango	UK 14304	4.04	Yohimbine	38.7	Yes	Yes
ADRA2A	Gqo5-NFAT-bla CHO-K1	BLA	UK 14304	11.5	Yohimbine	14.2	Yes	Yes
ADRB1	CRE-bla CHO-K1	BLA	(-)Denopamine	35.3	CPG-20712A	1.24	Yes	Yes
ADRB2	CRE-bla CHO-K1	BLA	Isoproterenol	3.896	Alprenolol	0.287	Yes	Yes
ADRB3	CRE-bla CHO-K1	BLA	BRL 37344	4.61	ICI-118551	4,460	Yes	Yes
AGTR1	bla U2OS	Tango	Angiotensin II	2.03	Telmisartan	0.025	Yes	Yes
AGTRL1	bla U2OS	Tango	Apellin-13	2.10	None		Yes	Yes
AVPR1A	NFAT-bla CHO-K1	BLA	dAVP	0.864	d(CH2)5(Tyr(Me)2)AV P	2.23	Yes	Yes
AVPR2	CRE-bla CHO-K1	BLA	dDAVP	0.501	d(CH2)5(Tyr(Et)2)AVP	111.3	Yes	Yes
B1	NFAT-bla CHO-K1	BLA	Bradykinin	17.1	Bradykinin (D-Arg-O Hyp3 IgI5 D-IgI7 Oic8)	128	Yes	Yes
B2	NFAT-bla CHO-K1	BLA	Bradykinin Acetate	1.72	HOE-140	73.8	Yes	Yes
C5AR1	Galpha15-NFAT-bla CHO-K1	BLA	C5a	5.16	None		Yes	Yes
CALCR	CRE-bla Freestyle 293F	BLA	sCT	0.003	sCT(8-32)	8.03	Yes	Yes
CALCRL:RAMP1	CRE-bla Freestyle 293F	BLA	CGRP	0.154	CGRP(8-37)	232	Yes	Yes
CALCRL:RAMP3	CRE-bla Freestyle 293F	BLA	Adrenomedullin	0.348	None		Yes	Yes
CaSR	Gqo5-NFAT-bla CHO-K1	BLA	Spermine	274,000	None		Yes	Yes
CCKAR	NFAT-bla HEK 293T	BLA	CCK-8	0.471	Lorglumide	360	Yes	Yes
CCKBR	NFAT-bla HEK 293T	BLA	CCK-8	4.457	None		Yes	Yes
CCR1	bla U2OS	Tango	Mip1-alpha	1.66	J113863	5.777	Yes	Yes
CCR2	bla U2OS	Tango	MCP-1	1.10	BMS CCR2 22	11.65	Yes	Yes
CCR3	bla U2OS	Tango	Eotaxin	72.2	None		Yes	Yes
CCR4	bla U2OS	Tango	MDC	11.2	None		Yes	Yes
CCR5	bla U2OS	Tango	Mip1-alpha	10.6	Maraviroc	0.087	Yes	Yes
CCR6	bla U2OS	Tango	Mip3-alpha	0.092	None		Yes	Yes
CCR7	bla U2OS	Tango	Mip3-beta	77.1	None		Yes	Yes
CMKLR1	bla U2OS	Tango	Chemerin	1.19	None		Yes	Yes
CNR1	Galpha15-NFAT-bla CHO-K1	BLA	CP-55940	4.66	AM251	2.349	Yes	Yes
CNR2	bla U2OS	Tango	CP-55940	30.5	None		Yes	Yes
CRHR1	CRE-bla CHO-K1	BLA	CRF	0.042	Astressin	1.535	Yes	Yes
CRHR2	CRE-bla CHO-K1	BLA	CRF	0.030	Astressin	0.849	Yes	Yes

ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 14 of 61

	•							
CXCR1	bla U2OS	Tango	IL-8	3.31	None		Yes	Yes
CXCR2	bla U2OS	Tango	IL-8	4.07	None		Yes	Yes
CXCR3	bla U2OS	Tango	I-TAC	7.26	None		Yes	Yes
CXCR4	bla U2OS	Tango	SDF1-alpha	12.6	None		Yes	Yes
CXCR6	bla U2OS	Tango	CXCL16	2.61	None		Yes	Yes
CXCR7	bla U2OS	Tango	SDF1-alpha	1.12	None		Yes	Yes
cysLT2	NFAT-bla CHO-K1	BLA	LTD4	51.3	None		Yes	Yes
D1	CRE-bla CHO-K1	BLA	Dihydrexidine	11.7	R(+)-SCH-23390	137.8	Yes	Yes
D2	Gqo5-NFAT-bla CHO-K1	BLA	Apomorphine	132.5	Perphenazine	0.480	Yes	Yes
EDG1	bla U2OS	Tango	S1P	0.987	VPC23019	47.3	Yes	Yes
EDG2	bla U2OS	Tango	LPA (18:1)	4,640	Ki16425	65.0	Yes	Yes
EDG3	Galpha15-NFAT-bla HEK 293T	BLA	S1P	274	CAY10444	23,700	Yes	Yes
EDG4	bla U2OS	Tango	LPA (18:1)	6830	None		Yes	Yes
EDG6	bla U2OS	Tango	S1P	168	None		Yes	Yes
EDG7	NFAT-bla HEK 293T	BLA	LPA (18:1)	956	VPC32183	3,020	Yes	Yes
EDG8	bla U2OS	Tango	S1P	85.8	None		Yes	Yes
EDNRA	bla U2OS	Tango	ET-1	0.017	BQ-123	1,090	Yes	Yes
EDNRA	NFAT-bla HEK 293T	BLA	ET-1	0.112	BQ-123	3,189	Yes	Yes
EDNRB	NFAT-bla HEK 293T	BLA	ET-1	0.149	BQ-788	572.8	Yes	Yes
F2RL1	bla U2OS	Tango	SLIGRL-NH2	365	None		Yes	Yes
FPRL1	Galpha15-NFAT-bla CHO-K1	BLA	WKYMVM peptide	2.22	None		Yes	Yes
GALR1	bla U2OS	Tango	Galanin	77.2	None		Yes	Yes
GALR2	bla U2OS	Tango	Galanin (1-30)	11.1	None		Yes	Yes
GCGR	CRE-bla CHO-K1	BLA	Glucagon	0.1734	None		Yes	Yes
GHSR	TREx-bla U2OS	Tango	None		Substance P	94.4		Yes
GIPR	CRE-bla HEK 293T	BLA	Gastric Inhibitory Peptide	0.015	None		Yes	Yes
GLP1R	CRE-bla CHO-K1	BLA	GLP-1	5.129	Excendin-3	118	Yes	Yes
GLP2R	bla U2OS	Tango	GLP-2	4.42	None		Yes	Yes
GnRHR	NFAT-bla CHO-K1	BLA	LH-RH	0.660	LH-RH antagonist	1,730	Yes	Yes
GPR1	bla U2OS	Tango	Chemerin	0.127	None		Yes	Yes
GPR10	NFAT-bla CHO-K1	BLA	PrRP20	0.051	None		Yes	Yes
GPR109A	bla U2OS	Tango	Nicotinic Acid	13,000	None		Yes	Yes
GPR119	TREx-CRE-bla CHO-K1	BLA	AR231453	4.67	None		Yes	Yes
GPR35	bla U2OS	Tango	Zaprinast	1,930	None		Yes	Yes
GPR44 (CRTH2)	bla U2OS	Tango	Indomethicin	875	BAY-u3405	19,300	Yes	Yes
GPR54	NFAT-bla CHO-K1	BLA	Metastin (45-54)	3.65	None		Yes	Yes
GPR8	bla U2OS	Tango	Neuropeptide B-29	27.8	None		Yes	Yes

ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# Page 15 of 61

GRPR	NFAT-bla CHO-K1	BLA	GRP	0.007	None		Yes	Yes
H1	NFAT-bla HEK 293T	BLA	Histamine	8.95	Triprolidine	9.82	Yes	Yes
H2	CRE-bla HEK 293T	BLA	Histamine	7.24	Tiotidine	71.8	Yes	Yes
H3	bla U2OS	Tango	Methylhistamine	31.8	Thioperamide	481.5	Yes	Yes
H4	bla U2OS	Tango	4-Methylhistamine	60.1	Thioperamide	385.6	Yes	Yes
HCRTR1	NFAT-bla CHO-K1	BLA	Orexin A	0.493	SB 408124	67.0	Yes	Yes
HCRTR2	Galpha15-NFAT-bla CHO-K1	BLA	Orexin B	1.48	EMPA	46.12	Yes	Yes
HTR1A	bla U2OS	Tango	5-HT	15.62	WAY-100635	435.8	Yes	Yes
HTR1A	Galpha15-NFAT-bla CHO-K1	BLA	5-HT	336	Methiothepin	35.5	Yes	Yes
HTR2A	bla U2OS	Tango	5-HT	5.497	Mianserin	68.4	Yes	Yes
HTR2B	NFAT-bla CHO-K1	BLA	5-HT	2.27	Clozapine	9.012	Yes	Yes
HTR7	CRE-bla CHO-K1	BLA	5-HT	8.38	SB269970	1.949	Yes	Yes
LTB4R	Galpha15-NFAT-bla CHO-K1	BLA	Leukotriene B4	58.4	None		Yes	Yes
M1	NFAT-bla CHO-K1	BLA	Carbachol	151	Scopolamine	4.50	Yes	Yes
M2	bla U2OS	Tango	Carbachol	5,691	Scopolamine	26.6	Yes	Yes
M3	NFAT-bla CHO-K1	BLA	Carbachol	172	Scopolamine	4.725	Yes	Yes
M4	bla U2OS	Tango	Carbachol	3,040	Scopolamine	0.392	Yes	Yes
M4	Gqo5-NFAT-bla CHO-K1	BLA	Carbachol	547	DAMP	3.01	Yes	Yes
M5	NFAT-bla CHO-K1	BLA	Carbachol	489	Scopolamine	3.22	Yes	Yes
MC1R	CRE-bla CHO-K1	BLA	NDP-alpha-MSH	0.173	None		Yes	Yes
MC2R	CRE-bla CHO-K1	BLA	ACTH (1-24)	0.046	None		Yes	Yes
MC3R	CRE-bla CHO-K1	BLA	NDP-alpha-MSH	0.034	SHU9119	1.03	Yes	Yes
MC4R	CRE-bla CHO-K1	BLA	alpha-MSH	0.645	SHU9119	0.041	Yes	Yes
MC5R	CRE-bla CHO-K1	BLA	NDP-alpha-MSH	0.140	None		Yes	Yes
MCHR1 (GPR24)	Gqi5-NFAT-bla CHO-K1	BLA	МСН	7.76	ATC0175	0.961	Yes	Yes
MCHR2	bla U2OS	Tango	MCH (6-17)	92.1	None		Yes	Yes
MCHR2	NFAT-bla CHO-K1	BLA	MCH (6-17)	0.973	None		Yes	Yes
MTNR1A	bla U2OS	Tango	Melatonin	0.713	Luzindole	1,940	Yes	Yes
MTNR1B	bla U2OS	Tango	Melatonin	83.6	None		Yes	Yes
NMUR1	NFAT-bla CHO-K1	BLA	NMU-25	0.051	None		Yes	Yes
NPSR1-A	NFAT-bla CHO-K1	BLA	Neuropeptide S	2.00	None		Yes	Yes
NPSR1-B	NFAT-bla CHO-K1	BLA	Neuropeptide S	11.2	None		Yes	Yes
NPY1R	bla U2OS	Tango	Neuropeptide Y	0.251	GR231118	7.19	Yes	Yes
NPY2R	bla U2OS	Tango	Neuropeptide Y	16.1	BIIE 0246	2.48	Yes	Yes
NTSR1	NFAT-bla CHO-K1	BLA	Neurotensin	0.307	None		Yes	Yes
OPRD1	bla U2OS	Tango	SNC80	97.2	SDM25N	9.10	Yes	Yes
OPRK1	bla U2OS	Tango	U50488	4.39	nor-BNI	1.26	Yes	Yes

ThermoFisher SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# Page 16 of 61

OPRK1	Gqo5-NFAT-bla CHO-K1	BLA	U50488	13.2	nor-BNI	1.26	Yes	Yes
OPRL1	bla U2OS	Tango	Nociceptin	4.92	UFP-101	27.8	Yes	Yes
OPRL1	Gqi5-NFAT-bla Freestyle 293F	BLA	Nociceptin	1.62	UFP-101	67.0	Yes	Yes
OPRM1	bla U2OS	Tango	DAMGO	19.968	beta-funaltrexamine	5.666	Yes	Yes
OXTR	Gqo5-NFAT-bla CHO-K1	BLA	Oxytocin	31.9	Atosiban	525.1	Yes	Yes
P2RY11	NFAT-bla CHO-K1	BLA	ATP	1,490	Suramin	13,500	Yes	Yes
P2RY2	NFAT-bla CHO-K1	BLA	ATP	677	Suramin	209,000	Yes	Yes
P2RY6	NFAT-bla CHO-K1	BLA	UDP	22.5	Suramin	71,300	Yes	Yes
PAC1	CRE-bla CHO-K1	BLA	PACAP	0.002	None		Yes	Yes
PTAFR	bla U2OS	Tango	PAF	14.47	ABT-491	0.024	Yes	Yes
PTGDR	CRE-bla CHO-K1	BLA	PGD2	1.46	AH6809	4494	Yes	Yes
PTGER1	NFAT-bla CHO-K1	BLA	PGE2	4.44	AH6809	1,560	Yes	Yes
PTGER2	CRE-bla CHO-K1	BLA	PGE2	1.57	AH6809	1,540	Yes	Yes
PTGIR	CRE-bla CHO-K1	BLA	lloprost	0.011	CAY10441	1.20	Yes	Yes
RLN3R1	bla U2OS	Tango	Relaxin-3	6.28	None		Yes	Yes
SCTR	CRE-bla CHO-K1	BLA	Secretin	0.003	None		Yes	Yes
SSTR1	bla U2OS	Tango	SST14	6.48	None		Yes	Yes
SSTR2	bla U2OS	Tango	SST14	0.191	CYN154806	39.3	Yes	Yes
SSTR5	bla U2OS	Tango	SST14	2.00	None		Yes	Yes
TACR1	bla U2OS	Tango	Sar9 Met(O2)11 Substance P	1.92	None		Yes	Yes
TACR2	NFAT-bla CHO-K1	BLA	(NIe10)-Neurokinin A (4-10)	1.30	MEN-10376	92.1	Yes	Yes
TACR3	bla U2OS	Tango	SSP Frag 6-11	0.780	None		Yes	Yes
TBXA2R	bla U2OS	Tango	U46619	123	L655240	21.4	Yes	Yes
VPAC1	CRE-bla CHO-K1	BLA	VIP	0.040	VIP1 Antagonist	2.01	Yes	Yes
VPAC2	CRE-bla CHO-K1	BLA	VIP	0.043	None		Yes	Yes

\*EC<sub>50</sub> and IC<sub>50</sub> values are representative

# **ThermoFisher** SCIENTIFIC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 17 of 61

# Parental Cell Lines Available for Screening

Cell Line	Tech- nology	Agonist	EC50 (nM)
CRE-bla CHO-K1	BLA	Forskolin	105
CRE-bla Freestyle 293F	BLA	Forskolin	1,500
CRE-bla HEK 293T	BLA	Forskolin	301
Galpha15-NFAT-bla CHO-K1	BLA	Thapsigargin	2.75
Galpha15-NFAT-bla HEK 293T	BLA	Thapsigargin + 5 nM PMA	1.41
Gqi5-NFAT-bla Freestyle 293F	BLA	PMA	1.42
Gqo5-NFAT-bla CHO-K1	BLA	Thapsigargin	3.16
NFAT-bla CHO-K1	BLA	Thapsigargin	3.69
NFAT-bla HEK 293T	BLA	Thapsigargin + 5 nM PMA	1.19

 $^{\ast}\text{EC}_{50}$  values are representative

Thermo Fisher

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 18 of 61

# **Cell Line-Specific Assay Conditions**

# ADORA1 - bla U2OS - Agonist Screen

ADORA1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of NECA (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADORA1 - bla U2OS - Antagonist Screen, Activated by NECA

ADORA1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of DPCPX (control antagonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist NECA at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADORA3 - bla U2OS - Agonist Screen

ADORA3-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of NECA (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADORA3 - bla U2OS - Antagonist Screen, Activated by NECA

ADORA3-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of MRS1220 (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist NECA at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA1A - NFAT-bla CHO-K1 - Agonist Screen

ADRA1A-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Phenylephrine (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA1A - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Phenylephrine

ADRA1A-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Prazosin (control antagonist starting concentration, 20,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Phenylephrine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 19 of 61

# ADRA1B - NFAT-bla CHO-K1 - Agonist Screen

ADRA1B-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Phenylephrine (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA1B - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Phenylephrine

ADRA1B-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Yohimbine (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Phenylephrine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of  $1 \ \mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA2A - bla U2OS - Agonist Screen

ADRA2A-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of UK 14304 (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA2A - bla U2OS - Antagonist Screen, Activated by UK 14304

ADRA2A-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \,\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Yohimbine (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist UK 14304 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA2A - Gqo5-NFAT-bla CHO-K1 - Agonist Screen

ADRA2A-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of UK 14304 (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRA2A - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by UK 14304

ADRA2A-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \mu$ L of a 10X serial dilution of Yohimbine (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \mu$ L of 10X control agonist UK 14304 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \mu$ L of  $1 \mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRB1 - CRE-bla CHO-K1 - Agonist Screen

ADRB1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of (-)Denopamine (control agonist starting concentration, 20,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

2	Screening Protocol and Assav Conditions
	Concerning i rotocol and Assay conditions

Revised 07-07-2023

# ADRB1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by (-)Denopamine

ADRB1-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of CPG-20712A (control antagonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist (-)Denopamine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRB2 - CRE-bla CHO-K1 - Agonist Screen

Thermo Fisher

SCIENTIFIC

ADRB2-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Isoproterenol (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 2 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRB2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by Isoproterenol

ADRB2-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Alprenolol (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Isoproterenol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 2 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRB3 - CRE-bla CHO-K1 - Agonist Screen

ADRB3-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of BRL 37344 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# ADRB3 - CRE-bla CHO-K1 - Antagonist Screen, Activated by BRL 37344

ADRB3-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of ICI-118551 (control antagonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist BRL 37344 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### AGTR1 - bla U2OS - Agonist Screen

AGTR1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Angiotensin II (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 21 of 61

# AGTR1 - bla U2OS - Antagonist Screen, Activated by Angiotensin II

AGTR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Telmisartan (control antagonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Angiotensin II at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator = Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# AGTRL1 - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

AGTRL1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Apellin-13 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## AGTRL1 - bla U2OS - Antagonist Screen, Activated by Apellin-13

AGTRL1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Apellin-13 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the AGTRL1-bla U2OS assay does not have an antagonist control.

### AVPR1A - NFAT-bla CHO-K1 - Agonist Screen

AVPR1A-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of dAVP (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### AVPR1A - NFAT-bla CHO-K1 - Antagonist Screen, Activated by dAVP

AVPR1A-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of d(CH2)5(Tyr(Me)2)AVP (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist dAVP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### AVPR2 - CRE-bla CHO-K1 - Agonist Screen

AVPR2-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 625,000 cells/mL. 32  $\mu$ L of cell suspension (20,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of dDAVP (control agonist starting concentration, 30 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### AVPR2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by dDAVP

AVPR2-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of d(CH2)5(Tyr(Et)2)AVP (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist dDAVP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **ThermoFisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 22 of 61

# B1 - NFAT-bla CHO-K1 - Agonist Screen

B1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Bradykinin (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# B1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Bradykinin

B1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Bradykinin (D-Arg-O Hyp3 IgI5 D-IgI7 Oic8) (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}C/5\%$  CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Bradykinin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# B2 - NFAT-bla CHO-K1 - Agonist Screen

B2-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Bradykinin Acetate (control agonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# B2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Bradykinin Acetate

B2-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of HOE-140 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Bradykinin Acetate at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# C5AR1 - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

C5AR1-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of C5a (control agonist starting concentration, 241 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# C5AR1 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by C5a

C5AR1-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist C5a at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the C5AR1-Galpha15-NFAT-bla CHO-K1 assay does not have an antagonist control.

# **ThermoFisher** SCLENTLFIC Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 23 of 61

# CALCR - CRE-bla Freestyle 293F - Agonist Screen

CALCR-CRE-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of sCT (control agonist starting concentration, 1 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CALCR - CRE-bla Freestyle 293F - Antagonist Screen, Activated by sCT

CALCR-CRE-bla Freestyle 293F cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of sCT(8-32) (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist sCT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CALCRL:RAMP1 - CRE-bla Freestyle 293F - Agonist Screen

CALCRL:RAMP1-CRE-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of CGRP (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CALCRL:RAMP1 - CRE-bla Freestyle 293F - Antagonist Screen, Activated by CGRP

CALCRL:RAMP1-CRE-bla Freestyle 293F cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of CGRP(8-37) (control antagonist starting concentration, 3,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist CGRP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CALCRL:RAMP3 - CRE-bla Freestyle 293F - Agonist Screen

CALCRL:RAMP3-CRE-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Adrenomedullin (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CALCRL:RAMP3 - CRE-bla Freestyle 293F - Antagonist Screen, Activated by Adrenomedullin

CALCRL:RAMP3-CRE-bla Freestyle 293F cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Adrenomedullin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CALCRL:RAMP3-CRE-bla Freestyle 293F assay does not have an antagonist control.

# ThermoFisherScreenSCIENTIFICScreen

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 24 of 61

# CaSR - Gqo5-NFAT-bla CHO-K1 - Agonist Screen

CaSR-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Spermine (control agonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CaSR - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Spermine

CaSR-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Spermine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CaSR-Gqo5-NFAT-bla CHO-K1 assay does not have an antagonist control.

# CCKAR - NFAT-bla HEK 293T - Agonist Screen

CCKAR-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CCK-8 (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCKAR - NFAT-bla HEK 293T - Antagonist Screen, Activated by CCK-8

CCKAR-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Lorglumide (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist CCK-8 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCKBR - NFAT-bla HEK 293T - Agonist Screen

CCKBR-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CCK-8 (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCKBR - NFAT-bla HEK 293T - Antagonist Screen, Activated by CCK-8

CCKBR-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist CCK-8 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CCKBR-NFAT-bla HEK 293T assay does not have an antagonist control.

# CCR1 - bla U2OS - Agonist Screen

CCR1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Mip1-alpha (control agonist starting concentration, 300 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# CCR1 - bla U2OS - Antagonist Screen, Activated by Mip1-alpha

CCR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of J113863 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Mip1-alpha at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR2 - bla U2OS - Agonist Screen

Thermo Fisher

SCIENTIFIC

CCR2-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of MCP-1 (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR2 - bla U2OS - Antagonist Screen, Activated by MCP-1

CCR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of a 10X serial dilution of BMS CCR2 22 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist MCP-1 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR3 - bla U2OS - Agonist Screen

CCR3-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of Eotaxin (control agonist starting concentration, 625 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR3 - bla U2OS - Antagonist Screen, Activated by Eotaxin

CCR3-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist Eotaxin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CCR3-bla U2OS assay does not have an antagonist control.

# CCR4 - bla U2OS - Agonist Screen

CCR4-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 468,750 cells/mL. 32  $\mu$ L of cell suspension (15,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of MDC (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR4 - bla U2OS - Antagonist Screen, Activated by MDC

CCR4-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}C/5\%$  CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist MDC at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CCR4-bla U2OS assay does not have an antagonist control.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 26 of 61

# CCR5 - bla U2OS - Agonist Screen

CCR5-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Mip1-alpha (control agonist starting concentration, 1,500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR5 - bla U2OS - Antagonist Screen, Activated by Mip1-alpha

CCR5-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Maraviroc (control antagonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Mip1-alpha at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR6 - bla U2OS - Agonist Screen

CCR6-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Mip3-alpha (control agonist starting concentration, 125 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## CCR6 - bla U2OS - Antagonist Screen, Activated by Mip3-alpha

CCR6-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Mip3-alpha at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CCR6-bla U2OS assay does not have an antagonist control.

#### CCR7 - bla U2OS - Agonist Screen

CCR7-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 µL of a 10X serial dilution of Mip3-beta (control agonist starting concentration, 400 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 µL of cell suspension (10,000 cells) is added to each well. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CCR7 - bla U2OS - Antagonist Screen, Activated by Mip3-beta

CCR7-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist Mip3-beta at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CCR7-bla U2OS assay does not have an antagonist control.

# CMKLR1 - bla U2OS - Agonist Screen

CMKLR1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Chemerin (control agonist starting concentration, 150 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 27 of 61

# CMKLR1 - bla U2OS - Antagonist Screen, Activated by Chemerin

CMKLR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Chemerin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CMKLR1-bla U2OS assay does not have an antagonist control.

# CNR1 - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

CNR1-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CP-55940 (control agonist starting concentration, 2,500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CNR1 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by CP-55940

CNR1-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of AM251 (control antagonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist CP-55940 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CNR2 - bla U2OS - Agonist Screen

CNR2-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CP-55940 (control agonist starting concentration, 2,500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CNR2 - bla U2OS - Antagonist Screen, Activated by CP-55940

CNR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist CP-55940 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CNR2-bla U2OS assay does not have an antagonist control.

# CRHR1 - CRE-bla CHO-K1 - Agonist Screen

CRHR1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CRF (control agonist starting concentration, 1 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CRHR1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by CRF

CRHR1-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Astressin (control antagonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist CRF at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# CRHR2 - CRE-bla CHO-K1 - Agonist Screen

CRHR2-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CRF (control agonist starting concentration, 1 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CRHR2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by CRF

CRHR2-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Astressin (control antagonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist CRF at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CXCR1 - bla U2OS - Agonist Screen

CXCR1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of IL-8 (control agonist starting concentration, 580 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CXCR1 - bla U2OS - Antagonist Screen, Activated by IL-8

CXCR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist IL-8 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR1-bla U2OS assay does not have an antagonist control.

# CXCR2 - bla U2OS - Agonist Screen

CXCR2-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of IL-8 (control agonist starting concentration, 290 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CXCR2 - bla U2OS - Antagonist Screen, Activated by IL-8

CXCR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist IL-8 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR2-bla U2OS assay does not have an antagonist control.

# CXCR3 - bla U2OS - Agonist Screen

CXCR3-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of I-TAC (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

# CXCR3 - bla U2OS - Antagonist Screen, Activated by I-TAC

CXCR3-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4 µL of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32 µL of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4 µL of 10X control agonist I-TAC at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR3-bla U2OS assay does not have an antagonist control.

# CXCR4 - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

CXCR4-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SDF1-alpha (control agonist starting concentration, 2,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CXCR4 - bla U2OS - Antagonist Screen, Activated by SDF1-alpha

CXCR4-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist SDF1-alpha at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR4-bla U2OS assay does not have an antagonist control.

# CXCR6 - bla U2OS - Agonist Screen

CXCR6-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CXCL16 (control agonist starting concentration, 200 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CXCR6 - bla U2OS - Antagonist Screen, Activated by CXCL16

CXCR6-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist CXCL16 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR6-bla U2OS assay does not have an antagonist control.

# CXCR7 - bla U2OS - Agonist Screen

CXCR7-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SDF1-alpha (control agonist starting concentration, 200 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **ThermoFisher** SCLENTLFIC Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 30 of 61

# CXCR7 - bla U2OS - Antagonist Screen, Activated by SDF1-alpha

CXCR7-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 μL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 μL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 μL of 10X control agonist SDF1-alpha at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the CXCR7-bla U2OS assay does not have an antagonist control.

# cysLT2 - NFAT-bla CHO-K1 - Agonist Screen

cysLT2-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of LTD4 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# cysLT2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by LTD4

cysLT2-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist LTD4 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the cysLT2-NFAT-bla CHO-K1 assay does not have an antagonist control.

# D1 - CRE-bla CHO-K1 - Agonist Screen

D1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Dihydrexidine (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# D1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by Dihydrexidine

D1-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of R(+)-SCH-23390 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Dihydrexidine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### D1 - CRE-bla CHO-K1 - Agonist Screen

D1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Dopamine (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 31 of 61

# D2 - Gqo5-NFAT-bla CHO-K1 - Agonist Screen

Thermo Físher

SCIENTIFIC

D2-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Apomorphine (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# D2 - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Apomorphine

D2-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Perphenazine (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Apomorphine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG1 - bla U2OS - Agonist Screen

EDG1-bla U2OS cells are grown in Growth Media (McCoy's 5A, 10% dialyzed FBS, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep). Cells are dissociated and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of S1P (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG1 - bla U2OS - Antagonist Screen, Activated by S1P

EDG1-bla U2OS cells are grown and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of VPC23019 (control antagonist starting concentration, 2,500 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist S1P at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG2 - bla U2OS - Agonist Screen

EDG2-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of LPA (18:1) (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG2 - bla U2OS - Antagonist Screen, Activated by LPA (18:1)

EDG2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Ki16425 (control antagonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist LPA (18:1) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG3 - Galpha15-NFAT-bla HEK 293T - Agonist Screen

EDG3-Galpha15-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of S1P (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

# EDG3 - Galpha15-NFAT-bla HEK 293T - Antagonist Screen, Activated by S1P

EDG3-Galpha15-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of CAY10444 (control antagonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist S1P at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG4 - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

EDG4-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 22-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of LPA (18:1) (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG4 - bla U2OS - Antagonist Screen, Activated by LPA (18:1)

EDG4-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 22-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist LPA (18:1) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the EDG4-bla U2OS assay does not have an antagonist control.

# EDG6 - bla U2OS - Agonist Screen

EDG6-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of S1P (control agonist starting concentration, 2,500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### EDG6 - bla U2OS - Antagonist Screen, Activated by S1P

EDG6-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist S1P at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the EDG6-bla U2OS assay does not have an antagonist control.

## EDG7 - NFAT-bla HEK 293T - Agonist Screen

EDG7-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL.  $32 \mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of LPA (18:1) (control agonist starting concentration, 25,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### EDG7 - NFAT-bla HEK 293T - Antagonist Screen, Activated by LPA (18:1)

EDG7-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of VPC32183 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist LPA (18:1) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of  $1 \ \mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 33 of 61

# EDG8 - bla U2OS - Agonist Screen

EDG8-bla U2OS cells are grown in Growth Media (McCoy's 5A, 10% dialyzed FBS, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep). Cells are dissociated and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of S1P (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDG8 - bla U2OS - Antagonist Screen, Activated by S1P

EDG8-bla U2OS cells are grown and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist S1P at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the EDG8-bla U2OS assay does not have an antagonist control.

# EDNRA - bla U2OS - Agonist Screen

EDNRA-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ET-1 (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDNRA - bla U2OS - Antagonist Screen, Activated by ET-1

EDNRA-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of BQ-123 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist ET-1 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDNRA - NFAT-bla HEK 293T - Agonist Screen

EDNRA-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ET-1 (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDNRA - NFAT-bla HEK 293T - Antagonist Screen, Activated by ET-1

EDNRA-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of BQ-123 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist ET-1 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **ThermoFisher** SCLENTLFIC Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 34 of 61

# EDNRB - NFAT-bla HEK 293T - Agonist Screen

EDNRB-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ET-1 (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# EDNRB - NFAT-bla HEK 293T - Antagonist Screen, Activated by ET-1

EDNRB-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of BQ-788 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist ET-1 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## F2RL1 - bla U2OS - Agonist Screen

F2RL1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 μg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 μL of a 10X serial dilution of SLIGRL-NH2 (control agonist starting concentration, 50,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 μL of cell suspension (10,000 cells) is added to each well. 4 μL of Assay Media is added to all wells to bring the final assay volume to 40 μL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 μL of 1 μM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### F2RL1 - bla U2OS - Antagonist Screen, Activated by SLIGRL-NH2

F2RL1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4 µL of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32 µL of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4 µL of 10X control agonist SLIGRL-NH2 at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the F2RL1-bla U2OS assay does not have an antagonist control.

### FPRL1 - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

FPRL1-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA,100 U/mL/100 µg/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32 µL of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of WKYMVM peptide (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# FPRL1 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by WKYMVM peptide

FPRL1-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \mu$ L of 10X control agonist WKYMVM peptide at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the FPRL1-Galpha15-NFAT-bla CHO-K1 assay does not have an antagonist control.

# GALR1 - bla U2OS - Agonist Screen

GALR1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Galanin (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 35 of 61

# GALR1 - bla U2OS - Antagonist Screen, Activated by Galanin

GALR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Galanin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GALR1-bla U2OS assay does not have an antagonist control.

## GALR2 - bla U2OS - Agonist Screen

Thermo Fisher

SCIENTIFIC

GALR2-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Galanin (1-30) (control agonist starting concentration, 4,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## GALR2 - bla U2OS - Antagonist Screen, Activated by Galanin (1-30)

GALR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Galanin (1-30) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GALR2-bla U2OS assay does not have an antagonist control.

### GCGR - CRE-bla CHO-K1 - Agonist Screen

GCGR-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 468,750 cells/mL. 32  $\mu$ L of cell suspension (15,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Glucagon (control agonist starting concentration, 8 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GCGR - CRE-bla CHO-K1 - Antagonist Screen, Activated by Glucagon

GCGR-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Glucagon at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GCGR-CRE-bla CHO-K1 assay does not have an antagonist control.

#### GHSR - TREx-bla U2OS - Antagonist Screen, Constitutively Activated

GHSR-TREx-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media, 10 ng/ml Doxycycline) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of Substance P (control antagonist starting concentration, 3,000 nM) or compounds are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to the wells. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



**Screening Protocol and Assay Conditions** 

Revised 07-07-2023

Page 36 of 61

# GIPR - CRE-bla HEK 293T - Agonist Screen

GIPR-CRE-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Gastric Inhibitory Peptide (control agonist starting concentration, 0.5 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GIPR - CRE-bla HEK 293T - Antagonist Screen, Activated by Gastric Inhibitory Peptide

GIPR-CRE-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Gastric Inhibitory Peptide at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GIPR-CRE-bla HEK 293T assay does not have an antagonist control.

# GLP1R - CRE-bla CHO-K1 - Agonist Screen

GLP1R-CRE-bla CHO-K1 cells are grown in Growth Media (DMEM, 10% dialyzed FBS, 25 mM HEPES, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep). Cells are dissociated and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of GLP-1 (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GLP1R - CRE-bla CHO-K1 - Antagonist Screen, Activated by GLP-1

GLP1R-CRE-bla CHO-K1 cells are grown and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Excendin-3 (control antagonist starting concentration, 30,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist GLP-1 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GLP2R - bla U2OS - Agonist Screen

GLP2R-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of GLP-2 (control agonist starting concentration, 2,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GLP2R - bla U2OS - Antagonist Screen, Activated by GLP-2

GLP2R-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4 µL of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32 µL of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4 µL of 10X control agonist GLP-2 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GLP2R-bla U2OS assay does not have an antagonist control.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 37 of 61

# GnRHR - NFAT-bla CHO-K1 - Agonist Screen

GnRHR-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 468,750 cells/mL. 32  $\mu$ L of cell suspension (15,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of LH-RH (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GnRHR - NFAT-bla CHO-K1 - Antagonist Screen, Activated by LH-RH

GnRHR-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of LH-RH antagonist (control antagonist starting concentration, 50,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist LH-RH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR1 - bla U2OS - Agonist Screen

GPR1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Chemerin (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## GPR1 - bla U2OS - Antagonist Screen, Activated by Chemerin

GPR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \mu$ L of 10X control agonist Chemerin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator at the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR1-bla U2OS assay does not have an antagonist control.

# GPR10 - NFAT-bla CHO-K1 - Agonist Screen

GPR10-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PrRP20 (control agonist starting concentration, 25 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR10 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by PrRP20

GPR10-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist PrRP20 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR10-NFAT-bla CHO-K1 assay does not have an antagonist control.

# GPR109A - bla U2OS - Agonist Screen

GPR109A-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Nicotinic Acid (control agonist starting concentration, 500,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

nermo Físher	Scr

# Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 38 of 61

# GPR109A - bla U2OS - Antagonist Screen, Activated by Nicotinic Acid

GPR109A-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Nicotinic Acid at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator . 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR109A-bla U2OS assay does not have an antagonist control.

## GPR119 - TREx-CRE-bla CHO-K1 - Agonist Screen

GPR119-TREx-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep, 0.1 µg/ml Doxycycline) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of AR231453 (control agonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR119 - TREx-CRE-bla CHO-K1 - Antagonist Screen, Activated by AR231453

GPR119-TREx-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist AR231453 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR119-TREx-CRE-bla CHO-K1 assay does not have an antagonist control.

## GPR120S - bla U2OS - Agonist Screen

GPR120S-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of GW9508 (control agonist starting concentration, 30,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR120S - bla U2OS - Antagonist Screen, Activated by GW9508

GPR120S-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 48 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}C/5\%$  CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist GW9508 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR120S-bla U2OS assay does not have an antagonist control.

# GPR35 - bla U2OS - Agonist Screen

GPR35-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Zaprinast (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 39 of 61

# GPR35 - bla U2OS - Antagonist Screen, Activated by Zaprinast

GPR35-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Zaprinast at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR35-bla U2OS assay does not have an antagonist control.

# GPR44 (CRTH2) - bla U2OS - Agonist Screen

GPR44 (CRTH2)-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 µL of a 10X serial dilution of Indomethicin (control agonist starting concentration, 150,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 µL of cell suspension (10,000 cells) is added to each well. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR44 (CRTH2) - bla U2OS - Antagonist Screen, Activated by Indomethicin

GPR44 (CRTH2)-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of a 10X serial dilution of BAYu3405 (control antagonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist Indomethicin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR54 - NFAT-bla CHO-K1 - Agonist Screen

GPR54-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Metastin (45-54) (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR54 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Metastin (45-54)

GPR54-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 μL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 μL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 μL of 10X control agonist Metastin (45-54) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 μL of 1 μM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR54-NFAT-bla CHO-K1 assay does not have an antagonist control.

# GPR8 - bla U2OS - Agonist Screen

GPR8-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Neuropeptide B-29 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GPR8 - bla U2OS - Antagonist Screen, Activated by Neuropeptide B-29

GPR8-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Neuropeptide B-29 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GPR8-bla U2OS assay does not have an antagonist control.

# **ThermoFisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 40 of 61

# GRPR - NFAT-bla CHO-K1 - Agonist Screen

GRPR-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of GRP (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# GRPR - NFAT-bla CHO-K1 - Antagonist Screen, Activated by GRP

GRPR-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist GRP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the GRPR-NFAT-bla CHO-K1 assay does not have an antagonist control.

# H1 - NFAT-bla HEK 293T - Agonist Screen

H1-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Histamine (control agonist starting concentration, 6,400 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H1 - NFAT-bla HEK 293T - Antagonist Screen, Activated by Histamine

H1-NFAT-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Triprolidine (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Histamine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H2 - CRE-bla HEK 293T - Agonist Screen

H2-CRE-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Histamine (control agonist starting concentration, 400 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H2 - CRE-bla HEK 293T - Antagonist Screen, Activated by Histamine

H2-CRE-bla HEK 293T cells are thawed and prepared as described above for the Agonist Screen.  $32 \,\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \,\mu$ L of a 10X serial dilution of Tiotidine (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \,\mu$ L of 10X control agonist Histamine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \,\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 41 of 61

# H3 - bla U2OS - Agonist Screen

H3-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Methylhistamine (control agonist starting concentration, 50,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H3 - bla U2OS - Antagonist Screen, Activated by Methylhistamine

H3-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \,\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Thioperamide (control antagonist starting concentration, 70,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Methylhistamine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H4 - bla U2OS - Agonist Screen

H4-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 22-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of 4-Methylhistamine (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# H4 - bla U2OS - Antagonist Screen, Activated by 4-Methylhistamine

H4-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 22-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Thioperamide (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist 4-Methylhistamine at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HCRTR1 - NFAT-bla CHO-K1 - Agonist Screen

HCRTR1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Orexin A (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HCRTR1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Orexin A

HCRTR1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of SB 408124 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Orexin A at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HCRTR2 - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

HCRTR2-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Orexin B (control agonist starting concentration, 200 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 42 of 61

# HCRTR2 - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Orexin B

HCRTR2-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Orexin B at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the HCRTR2-Galpha15-NFAT-bla CHO-K1 assay does not have an antagonist control.

# HTR1A - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

HTR1A-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of 5-HT (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR1A - bla U2OS - Antagonist Screen, Activated by 5-HT

HTR1A-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of WAY-100635 (control antagonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist 5-HT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR1A - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

HTR1A-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 468,750 cells/mL. 32 µL of cell suspension (15,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of 5-HT (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR1A - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by 5-HT

HTR1A-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Methiothepin (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist 5-HT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## HTR2A - bla U2OS - Agonist Screen

HTR2A-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of 5-HT (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **ThermoFisher** SCLENTLFIC Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 43 of 61

# HTR2A - bla U2OS - Antagonist Screen, Activated by 5-HT

HTR2A-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Mianserin (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist 5-HT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR2B - NFAT-bla CHO-K1 - Agonist Screen

HTR2B-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of 5-HT (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR2B - NFAT-bla CHO-K1 - Antagonist Screen, Activated by 5-HT

HTR2B-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 μL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 μL of a 10X serial dilution of Clozapine (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 μL of 10X control agonist 5-HT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 μL of 1 μM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR7 - CRE-bla CHO-K1 - Agonist Screen

HTR7-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of 5-HT (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# HTR7 - CRE-bla CHO-K1 - Antagonist Screen, Activated by 5-HT

HTR7-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of SB269970 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist 5-HT at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 4 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# LTB4R - Galpha15-NFAT-bla CHO-K1 - Agonist Screen

LTB4R-Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Leukotriene B4 (control agonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 4 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

Page 44 of 61

# LTB4R - Galpha15-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Leukotriene B4

LTB4R-Galpha15-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \mu$ L of 10X control agonist Leukotriene B4 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 4 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the LTB4R-Galpha15-NFAT-bla CHO-K1 assay does not have an antagonist control.

# M1 - NFAT-bla CHO-K1 - Agonist Screen

Thermo Físher

SCIENTIFIC

M1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Carbachol (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# M1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol

M1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Scopolamine (control antagonist starting concentration, 600 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## M2 - bla U2OS - Agonist Screen

M2-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Carbachol (control agonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## M2 - bla U2OS - Antagonist Screen, Activated by Carbachol

M2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Scopolamine (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## M3 - NFAT-bla CHO-K1 - Agonist Screen

M3-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Carbachol (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 45 of 61

# M3 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol

M3-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Scopolamine (control antagonist starting concentration, 600 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# M4 - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

M4-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 µL of a 10X serial dilution of Carbachol (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 µL of cell suspension (10,000 cells) is added to each well. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## M4 - bla U2OS - Antagonist Screen, Activated by Carbachol

M4-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of a 10X serial dilution of Scopolamine (control antagonist starting concentration, 600 nM) or compounds are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## M4 - Gqo5-NFAT-bla CHO-K1 - Agonist Screen

M4-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS) to a concentration of 312,500 cells/mL.  $32 \mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \mu$ L of a 10X serial dilution of Carbachol (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate.  $4 \mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# M4 - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol

M4-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of DAMP (control antagonist starting concentration, 600 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# M5 - NFAT-bla CHO-K1 - Agonist Screen

M5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Carbachol (control agonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# M5 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Carbachol

M5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Scopolamine (control antagonist starting concentration, 600 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Carbachol at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 46 of 61

# MC1R - CRE-bla CHO-K1 - Agonist Screen

MC1R-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of NDP-alpha-MSH (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC1R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH

MC1R-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist NDP-alpha-MSH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MC1R-CRE-bla CHO-K1 assay does not have an antagonist control.

# MC2R - CRE-bla CHO-K1 - Agonist Screen

MC2R-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of ACTH (1-24) (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC2R - CRE-bla CHO-K1 - Antagonist Screen, Activated by ACTH (1-24)

MC2R-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist ACTH (1-24) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MC2R-CRE-bla CHO-K1 assay does not have an antagonist control.

# MC3R - CRE-bla CHO-K1 - Agonist Screen

MC3R-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of NDP-alpha-MSH (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC3R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH

MC3R-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of SHU9119 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist NDP-alpha-MSH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 47 of 61

# MC4R - CRE-bla CHO-K1 - Agonist Screen

MC4R-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32 µL of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of alpha-MSH (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC4R - CRE-bla CHO-K1 - Antagonist Screen, Activated by alpha-MSH

MC4R-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of SHU9119 (control antagonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist alpha-MSH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC5R - CRE-bla CHO-K1 - Agonist Screen

MC5R-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of NDP-alpha-MSH (control agonist starting concentration, 1 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MC5R - CRE-bla CHO-K1 - Antagonist Screen, Activated by NDP-alpha-MSH

MC5R-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist NDP-alpha-MSH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MC5R-CRE-bla CHO-K1 assay does not have an antagonist control.

# MCHR1 (GPR24) - Gqi5-NFAT-bla CHO-K1 - Agonist Screen

MCHR1 (GPR24)-Gqi5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32 µL of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of MCH (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MCHR1 (GPR24) - Gqi5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by MCH

MCHR1 (GPR24)-Gqi5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \mu$ L of a 10X serial dilution of ATC0175 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \mu$ L of 10X control agonist MCH at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## MCHR2 - bla U2OS - Agonist Screen

MCHR2-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 4  $\mu$ L of a 10X serial dilution of MCH (6-17) (control agonist starting concentration, 30,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 48 of 61

# MCHR2 - bla U2OS - Antagonist Screen, Activated by MCH (6-17)

MCHR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist MCH (6-17) at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MCHR2-bla U2OS assay does not have an antagonist control.

# MCHR2 - NFAT-bla CHO-K1 - Agonist Screen

MCHR2-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of MCH (6-17) (control agonist starting concentration, 3,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MCHR2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by MCH (6-17)

MCHR2-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist MCH (6-17) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MCHR2-NFAT-bla CHO-K1 assay does not have an antagonist control.

# MTNR1A - bla U2OS - Agonist Screen

MTNR1A-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Melatonin (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MTNR1A - bla U2OS - Antagonist Screen, Activated by Melatonin

MTNR1A-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \,\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Luzindole (control antagonist starting concentration, 100,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Melatonin at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MTNR1B - bla U2OS - Agonist Screen

MTNR1B-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 µL of a 10X serial dilution of Melatonin (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 µL of cell suspension (10,000 cells) is added to each well. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# MTNR1B - bla U2OS - Antagonist Screen, Activated by Melatonin

MTNR1B-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist Melatonin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the MTNR1B-bla U2OS assay does not have an antagonist control.

# **ThermoFisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 49 of 61

# NMUR1 - NFAT-bla CHO-K1 - Agonist Screen

NMUR1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 78,125 cells/mL. 32  $\mu$ L of cell suspension (2,500 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of NMU-25 (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NMUR1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by NMU-25

NMUR1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist NMU-25 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of  $1 \ \mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the NMUR1-NFAT-bla CHO-K1 assay does not have an antagonist control.

# NPSR1-A - NFAT-bla CHO-K1 - Agonist Screen

NPSR1-A-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Neuropeptide S (control agonist starting concentration, 300 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NPSR1-A - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Neuropeptide S

NPSR1-A-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Neuropeptide S at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the NPSR1-A-NFAT-bla CHO-K1 assay does not have an antagonist control.

# NPSR1-B - NFAT-bla CHO-K1 - Agonist Screen

NPSR1-B-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Neuropeptide S (control agonist starting concentration, 300 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NPSR1-B - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Neuropeptide S

NPSR1-B-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Neuropeptide S at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the NPSR1-B-NFAT-bla CHO-K1 assay does not have an antagonist control.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 50 of 61

# NPY1R - bla U2OS - Agonist Screen

NPY1R-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Neuropeptide Y (control agonist starting concentration, 30 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NPY1R - bla U2OS - Antagonist Screen, Activated by Neuropeptide Y

NPY1R-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of GR231118 (control antagonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Neuropeptide Y at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NPY2R - bla U2OS - Agonist Screen

NPY2R-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Neuropeptide Y (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NPY2R - bla U2OS - Antagonist Screen, Activated by Neuropeptide Y

NPY2R-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of BIIE 0246 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Neuropeptide Y at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NTSR1 - NFAT-bla CHO-K1 - Agonist Screen

NTSR1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Neurotensin (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NTSR1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by Neurotensin

NTSR1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Neurotensin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the NTSR1-NFAT-bla CHO-K1 assay does not have an antagonist control.

The	rmo	Físh	er
SC	ENT	<b>FIF</b>	IC

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 51 of 61

# OPRD1 - bla U2OS - Agonist Screen

OPRD1-bla U2OS cells are grown in Growth Media (McCoy's 5A, 10% dialyzed FBS, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep). Cells are dissociated and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of SNC80 (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRD1 - bla U2OS - Antagonist Screen, Activated by SNC80

OPRD1-bla U2OS cells are grown and prepared as described above for the Agonist Screen.  $32 \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SDM25N (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist SNC80 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **OPRK1 - bla U2OS - Agonist Screen**

OPRK1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA,100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of U50488 (control agonist starting concentration, 150 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRK1 - bla U2OS - Antagonist Screen, Activated by U50488

OPRK1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of nor-BNI (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist U50488 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **OPRK1 - Gqo5-NFAT-bla CHO-K1 - Agonist Screen**

OPRK1-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of U50488 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRK1 - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by U50488

OPRK1-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of nor-BNI (control antagonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist U50488 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 52 of 61

# OPRL1 - bla U2OS - Agonist Screen

OPRL1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Nociceptin (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRL1 - bla U2OS - Antagonist Screen, Activated by Nociceptin

OPRL1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of UFP-101 (control antagonist starting concentration, 25,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Nociceptin at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator b Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRL1 - Gqi5-NFAT-bla Freestyle 293F - Agonist Screen

OPRL1-Gqi5-NFAT-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 234,375 cells/mL. 32 µL of cell suspension (7,500 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Nociceptin (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OPRL1 - Gqi5-NFAT-bla Freestyle 293F - Antagonist Screen, Activated by Nociceptin

OPRL1-Gqi5-NFAT-bla Freestyle 293F cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of UFP-101 (control antagonist starting concentration, 25,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist Nociceptin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **OPRM1** - bla U2OS - Agonist Screen

OPRM1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA,100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 µL of a 10X serial dilution of DAMGO (control agonist starting concentration, 3,000 nM) or compounds are added to appropriate wells of a 384-well TC-Treated assay plate. 32 µL of cell suspension (10,000 cells) is added to each well. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **OPRM1** - bla U2OS - Antagonist Screen, Activated by DAMGO

OPRM1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 4  $\mu$ L of a 10X serial dilution of betafunaltrexamine (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of a TC-Treated assay plate. 32  $\mu$ L of cell suspension is added to the wells and pre-incubated at 37°C/5% CO2 in a humidified incubator with compounds and control antagonist titration for 30 minutes. 4  $\mu$ L of 10X control agonist DAMGO at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 16-24 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# OXTR - Gqo5-NFAT-bla CHO-K1 - Agonist Screen

OXTR-Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Oxytocin (control agonist starting concentration, 2,500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# OXTR - Gqo5-NFAT-bla CHO-K1 - Antagonist Screen, Activated by Oxytocin

OXTR-Gqo5-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \,\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \,\mu$ L of a 10X serial dilution of Atosiban (control antagonist starting concentration, 50,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \,\mu$ L of 10X control agonist Oxytocin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \,\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# P2RY11 - NFAT-bla CHO-K1 - Agonist Screen

Thermo Físher

SCIENTIFIC

P2RY11-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ATP (control agonist starting concentration, 20,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## P2RY11 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by ATP

P2RY11-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Suramin (control antagonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist ATP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# P2RY2 - NFAT-bla CHO-K1 - Agonist Screen

P2RY2-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ATP (control agonist starting concentration, 30,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### P2RY2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by ATP

P2RY2-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 μL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 μL of a 10X serial dilution of Suramin (control antagonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 μL of 10X control agonist ATP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 μL of 1 μM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

### P2RY6 - NFAT-bla CHO-K1 - Agonist Screen

P2RY6-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of UDP (control agonist starting concentration, 3,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

# P2RY6 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by UDP

P2RY6-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of Suramin (control antagonist starting concentration, 1,000,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist UDP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PAC1 - CRE-bla CHO-K1 - Agonist Screen

Thermo Físher

SCIENTIFIC

PAC1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PACAP (control agonist starting concentration, 1 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PAC1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by PACAP

PAC1-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist PACAP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the PAC1-CRE-bla CHO-K1 assay does not have an antagonist control.

# PTAFR - bla U2OS - Agonist Screen

PTAFR-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PAF (control agonist starting concentration, 500 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTAFR - bla U2OS - Antagonist Screen, Activated by PAF

PTAFR-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of ABT-491 (control antagonist starting concentration, 5 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist PAF at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGDR - CRE-bla CHO-K1 - Agonist Screen

PTGDR-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PGD2 (control agonist starting concentration, 40 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGDR - CRE-bla CHO-K1 - Antagonist Screen, Activated by PGD2

PTGDR-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of AH6809 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist PGD2 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 55 of 61

# PTGER1 - NFAT-bla CHO-K1 - Agonist Screen

PTGER1-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PGE2 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGER1 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by PGE2

PTGER1-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of AH6809 (control antagonist starting concentration, 50,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist PGE2 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGER2 - CRE-bla CHO-K1 - Agonist Screen

PTGER2-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PGE2 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGER2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by PGE2

PTGER2-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of AH6809 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist PGE2 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGIR - CRE-bla CHO-K1 - Agonist Screen

PTGIR-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% CD-treated FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of lloprost (control agonist starting concentration, 200 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# PTGIR - CRE-bla CHO-K1 - Antagonist Screen, Activated by Iloprost

PTGIR-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of a 10X serial dilution of CAY10441 (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist lloprost at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

# RLN3R1 - bla U2OS - Agonist Screen

RLN3R1-bla U2OS cells are thawed and resuspended in Assay Media (Freestyle media) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Relaxin-3 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# RLN3R1 - bla U2OS - Antagonist Screen, Activated by Relaxin-3

RLN3R1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32  $\mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Relaxin-3 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the RLN3R1-bla U2OS assay does not have an antagonist control.

# SCTR - CRE-bla CHO-K1 - Agonist Screen

SCTR-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Secretin (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# SCTR - CRE-bla CHO-K1 - Antagonist Screen, Activated by Secretin

SCTR-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $4 \ \mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes.  $4 \ \mu$ L of 10X control agonist Secretin at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator.  $8 \ \mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the SCTR-CRE-bla CHO-K1 assay does not have an antagonist control.

# SSTR1 - bla U2OS - Agonist Screen

SSTR1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SST14 (control agonist starting concentration, 610 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# SSTR1 - bla U2OS - Antagonist Screen, Activated by SST14

SSTR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist SST14 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the SSTR1-bla U2OS assay does not have an antagonist control.

# SSTR2 - bla U2OS - Agonist Screen

SSTR2-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SST14 (control agonist starting concentration, 610 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Screening Protocol and Assay Conditions

Revised 07-07-2023

# SSTR2 - bla U2OS - Antagonist Screen, Activated by SST14

SSTR2-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of CYN154806 (control antagonist starting concentration, 5,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist SST14 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# SSTR5 - bla U2OS - Agonist Screen

Thermo Físher

SCIENTIFIC

SSTR5-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of SST14 (control agonist starting concentration, 610 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## SSTR5 - bla U2OS - Antagonist Screen, Activated by SST14

SSTR5-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist SST14 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the SSTR5-bla U2OS assay does not have an antagonist control.

### TACR1 - bla U2OS - Agonist Screen

TACR1-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Substance P (control agonist starting concentration, 300 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### TACR1 - bla U2OS - Antagonist Screen, Activated by Substance P

TACR1-bla U2OS cells are thawed and prepared as described above for the Agonist Screen.  $32 \ \mu$ L of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}$ C/5% CO2 in a humidified incubator. 4  $\mu$ L of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at  $37^{\circ}$ C/5% CO2 in a humidified incubator with cells for 30 minutes. 4  $\mu$ L of 10X control agonist Substance P at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at  $37^{\circ}$ C/5% CO2 in a humidified incubator + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the TACR1-bla U2OS assay does not have an antagonist control.

### TACR2 - NFAT-bla CHO-K1 - Agonist Screen

TACR2-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of (NIe10)-Neurokinin A (4-10) (control agonist starting concentration, 300 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

<b>Thermo Fisher</b>	Screening Protocol and Assay Conditions
SCIENIFIC	Deviced 07 07 2

Revised 07-07-2023

Page 58 of 61

# TACR2 - NFAT-bla CHO-K1 - Antagonist Screen, Activated by (Nle10)-Neurokinin A (4-10)

TACR2-NFAT-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of MEN-10376 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist (Ne10)-Neurokinin A (4-10) at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# TACR3 - bla U2OS - Agonist Screen

TACR3-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of SSP Frag 6-11 (control agonist starting concentration, 312.5 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# TACR3 - bla U2OS - Antagonist Screen, Activated by SSP Frag 6-11

TACR3-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist SSP Frag 6-11 at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the TACR3-bla U2OS assay does not have an antagonist control.

## TBXA2R - bla U2OS - Agonist Screen

TBXA2R-bla U2OS cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of U46619 (control agonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

#### TBXA2R - bla U2OS - Antagonist Screen, Activated by U46619

TBXA2R-bla U2OS cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of L655240 (control antagonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist U46619 at the predetermined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## VPAC1 - CRE-bla CHO-K1 - Agonist Screen

VPAC1-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32 µL of cell suspension (10,000 cells) is added to each well of a 384well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of VIP (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# **Thermo Fisher**

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 59 of 61

# VPAC1 - CRE-bla CHO-K1 - Antagonist Screen, Activated by VIP

VPAC1-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of VIP1 Antagonist (control antagonist starting concentration, 1,000 nM) or compounds are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist VIP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# VPAC2 - CRE-bla CHO-K1 - Agonist Screen

VPAC2-CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 1% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 32  $\mu$ L of cell suspension (10,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of VIP (control agonist starting concentration, 10 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# VPAC2 - CRE-bla CHO-K1 - Antagonist Screen, Activated by VIP

VPAC2-CRE-bla CHO-K1 cells are thawed and prepared as described above for the Agonist Screen. 32 µL of cell suspension is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of 10X compounds or Assay Media are added to appropriate wells of the plate and pre-incubated at 37°C/5% CO2 in a humidified incubator with cells for 30 minutes. 4 µL of 10X control agonist VIP at the pre-determined EC80 concentration is added to wells containing the control antagonist or compounds. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader. At this time, the VPAC2-CRE-bla CHO-K1 assay does not have an antagonist control.

**ThermoFisher** 

# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 60 of 61

# Parental Cell Line-Specific Assay Conditions

# CRE-bla CHO-K1 - Agonist Screen

CRE-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 625,000 cells/mL. 32  $\mu$ L of cell suspension (20,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Forskolin (control agonist starting concentration, 10,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CRE-bla Freestyle 293F - Agonist Screen

CRE-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 625,000 cells/mL. 32 µL of cell suspension (20,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Forskolin (control agonist starting concentration, 40,000 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# CRE-bla HEK 293T - Agonist Screen

CRE-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 625,000 cells/mL. 32  $\mu$ L of cell suspension (20,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Forskolin (control agonist starting concentration, 25,000 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Galpha15-NFAT-bla CHO-K1 - Agonist Screen

Galpha15-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32 µL of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Thapsigargin (control agonist starting concentration, 80 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Galpha15-NFAT-bla HEK 293T - Agonist Screen

Galpha15-NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Thapsigargin + 5 nM PMA (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# Gqi5-NFAT-bla Freestyle 293F - Agonist Screen

Gqi5-NFAT-bla Freestyle 293F cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 625,000 cells/mL. 32  $\mu$ L of cell suspension (20,000 cells) is added to each well of a 384-well Poly-D-Lysine assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of PMA (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.



# **Screening Protocol and Assay Conditions**

Revised 07-07-2023

Page 61 of 61

# Gqo5-NFAT-bla CHO-K1 - Agonist Screen

Gqo5-NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100 µg/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32 µL of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 4 µL of a 10X serial dilution of Thapsigargin (control agonist starting concentration, 80 nM) or compounds are added to appropriate wells of the plate. 4 µL of Assay Media is added to all wells to bring the final assay volume to 40 µL. The plate is incubated for 5 hours at  $37^{\circ}C/5\%$  CO2 in a humidified incubator. 8 µL of 1 µM Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

# NFAT-bla CHO-K1 - Agonist Screen

NFAT-bla CHO-K1 cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Thapsigargin (control agonist starting concentration, 80 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.

## NFAT-bla HEK 293T - Agonist Screen

NFAT-bla HEK 293T cells are thawed and resuspended in Assay Media (DMEM, 10% dialyzed FBS, 25 mM HEPES pH 7.3, 0.1 mM NEAA, 100 U/mL/100  $\mu$ g/mL Pen/Strep) to a concentration of 156,250 cells/mL. 32  $\mu$ L of cell suspension (5,000 cells) is added to each well of a 384-well TC-Treated assay plate. Cells in Assay Media are incubated for 16-24 hours in the plate at 37°C/5% CO2 in a humidified incubator. 4  $\mu$ L of a 10X serial dilution of Thapsigargin + 5 nM PMA (control agonist starting concentration, 100 nM) or compounds are added to appropriate wells of the plate. 4  $\mu$ L of Assay Media is added to all wells to bring the final assay volume to 40  $\mu$ L. The plate is incubated for 5 hours at 37°C/5% CO2 in a humidified incubator. 8  $\mu$ L of 1  $\mu$ M Substrate + Solution D Loading Solution is added to each well and the plate is incubated for 2 hours at room temperature. The plate is read on a fluorescence plate reader.